



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 1 705 247 A1

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
27.09.2006 Bulletin 2006/39

(51) Int Cl:  
C12N 15/09 (2006.01) C12N 1/15 (2006.01)  
C12N 1/19 (2006.01) C12N 1/21 (2006.01)  
C12N 5/10 (2006.01) C12N 9/02 (2006.01)  
C12P 17/08 (2006.01) C07K 14/00 (2006.01)

(21) Application number: 04799902.4

(22) Date of filing: 25.11.2004

(86) International application number:  
PCT/JP2004/017906

(87) International publication number:  
WO 2005/052152 (09.06.2005 Gazette 2005/23)

(84) Designated Contracting States:  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR  
Designated Extension States:  
AL HR LT LV MK YU

(30) Priority: 27.11.2003 JP 2003396828


(71) Applicants:  
• MERCIAN CORPORATION  
Chuo-ku,  
Tokyo 104-8305 (JP)  
• Eisai Co., Ltd.  
Tokyo 112-0002 (JP)

(72) Inventors:  
• MACHIDA, Kazuhiro  
Iwata-shi,  
Shizuoka (JP)  
• NAKASHIMA, Takashi  
Naka-gun, Kanagawa (JP)  
• ARITOKU, Yasuhide  
Iwata-shi, Shizuoka (JP)  
• TSUCHIDA, Toshio  
Iwata-shi, Shizuoka (JP)


(74) Representative: HOFFMANN EITLE  
Patent- und Rechtsanwälte  
Arabellastrasse 4  
81925 München (DE)

(54) **DNA PARTICIPATING IN HYDROXYLATION OF MACROLIDE COMPOUND**

(57) The present invention provides a DNA participating in biological transformation of a macrolide compound 11107B. The present invention provides, particularly, a DNA participating in biological transformation of a macrolide compound 11107B represented by the formula (I) into a 16-position hydroxy macrolide compound 11107D represented by the formula (II), the DNA encoding a protein having 16-position hydroxylating enzymatic activity or ferredoxin, to a method of isolating the DNA, to a protein encoded by the DNA, a plasmid carrying the DNA, a transformant obtained by transforming using the plasmid and a method of producing a 16-position hydroxy compound by using the transformant.



EP 1 705 247 A1




## Description

## Field of the invention


[0001] The present invention relates to a DNA participating in hydroxylation of a macrolide compound, a method of isolating it, a protein encoded by the DNA, a plasmid carrying the DNA, a transformant obtained by the transformation of the plasmid and a method of producing a 16-position hydroxy macrolide compound by using the transformant.

## Prior Art

[0002] The 12-membered ring macrolide compound 11107D represented by the formula (II):



is a 12-membered ring macrolide compound having an excellent antitumor activity and has been found, together with a 12-membered ring macrolide compound 11107B represented by the formula (I):




from a cultured product of a *Streptomyces* sp. Mer-11107 strain (WO02/060890). The macrolide compound 11107D corresponds to a 16-position hydroxylated body of the macrolide compound 11107B. The productivity of the macrolide compound 11107D is lower than that of the macrolide compound 11107B and it has been therefore desired to establish an efficient method of producing the macrolide compound 11107D.

## Disclosure of the invention


[0003] The purpose of the present invention is to find a DNA participating in hydroxylation of the macrolide compound 11107B to thereby provide a novel method of producing the macrolide compound 11107D.

[0004] The present invention relates to the following (1) to (15):

(1) a DNA participating in biological transformation of a macrolide compound (hereinafter referred to as a macrolide compound 11107B) represented by the formula (I):



into a 16-position hydroxy macrolide compound (hereinafter referred to as a macrolide compound 11107D) represented by the formula (II):



the DNA being an isolated and pure DNA comprising a DNA encoding a protein having 16-position hydroxylating enzymatic activity or ferredoxin, partly or entirely or its variant;

(2) the DNA described in (1), which is characterized by the following (a), (b) or (c):

(a) a DNA encoding a protein having the enzymatic activity in hydroxylating the 16-position of the macrolide compound 11107B and selected from the group consisting of a continuous nucleotide sequence from the base 1322 to base 2548 of the sequence No. 1; a continuous nucleotide sequence from the base 420 to base 1604 of the sequence No. 2; and a continuous nucleotide sequence from the base 172 to base 1383 of the sequence No. 3;

(b) a DNA which is a variant of the DNA described in the above (a);

(i) is hybridized with the DNA described in the above (a) under a stringent condition; and

(ii) encodes a protein having enzymatic activity in hydroxylating the 16-position of the macrolide compound 11107B; and

(c) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA described in the above (a) or (b) though it is not hybridized with the DNA described in the above (a) under a stringent condition because of the degeneracy of a gene codon;

(3) a protein encoded by the DNA as described in (2);

(4) a self-replicative or integrating replicative recombinant plasmid carrying the DNA as described in (2);

(5) a transformant into which the recombinant plasmid described in (4) transforms;

(6) a method of isolating a DNA encoding a protein having enzymatic activity in hydroxylating the 16-position of the macrolide compound 11107B, the method characterized by using the DNA as described in (2) or a DNA constituted of a part of the DNA as a probe or a primer;

(7) the DNA described in (1), which is characterized by the following (d), (e) or (f):

(d) a DNA encoding ferredoxin and selected from the group consisting of a continuous nucleotide sequence from the base 2564 to base 2761 of the sequence No. 1, a continuous nucleotide sequence from the base 1643 to base 1834 of the sequence No. 2 and a continuous nucleotide sequence from the base 1399 to base 1593 of the sequence No. 3;

(e) a DNA which is a variant of the DNA represented by the above (d);

(i) is hybridized with the DNA described in the above (d) under a stringent condition; and

(ii) encodes a protein having a ferredoxin function; and

(f) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA represented by the above (d) or (e) though it is not hybridized with the DNA described in the above (d) under a stringent condition because of the degeneracy of a gene codon;


(8) a protein encoded by the DNA as described in (7);

(9) a self-replicative or integrating replicative recombinant plasmid carrying the DNA as described in (7);


(10) a transformant into which the recombinant plasmid as described in (9) transforms;

(11) a method of isolating a DNA encoding a protein having a ferredoxin function, the method characterized by using the DNA as described in (7) or a DNA constituted of a part of the DNA as a probe or a primer;

(12) a method of producing a 16-position hydroxy macrolide compound, the method comprises the steps of culturing the transformant as described in (5) or (10) in a medium; bringing the proliferated transformant into contact with a macrolide compound represented by the formula (III):



(wherein W represents



[0005] R12, R16b, R17a, R17b, R18, R20a, R20b, R21a and R21b, which may be the same as or different from, respectively represent:

- (1) hydrogen atom;
- (2) a C<sub>1-22</sub> alkyl group which may have a substituent;
- (3) -OR (wherein R represents:

- 1) hydrogen atom; or
- 2) a C<sub>1-22</sub> alkyl group;
- 3) a C<sub>7-22</sub> aralkyl group;
- 4) a 5-membered to 14-membered heteroaryloxyalkyl group;
- 5) a C<sub>2-22</sub> alkanoyl group;
- 6) a C<sub>7-15</sub> aroyl group;
- 7) a C<sub>3-23</sub> unsaturated alkanoyl group;
- 8) -COR<sup>oo</sup> (wherein R<sup>oo</sup> represents:

- 8-1) a 5-membered to 14-membered heteroaryloxyaryl group;

8-2) a C<sub>1-22</sub> alkoxy group;  
 8-3) an unsaturated C<sub>2-22</sub> alkoxy group;  
 8-4) a C<sub>6-14</sub> aryloxy group;  
 8-5) a 5-membered to 14-membered heteroaryloxy group; or  
 8-6) a 3-membered to 14-membered nitrogen-containing non-aromatic heterocyclic group, each of which  
 may have a substituent;

9) a C<sub>1-22</sub> alkylsulfonyl group;  
 10) a C<sub>6-14</sub> arylsulfonyl group; or  
 11) -SiR<sup>a1</sup>R<sup>a2</sup>R<sup>a3</sup>, (wherein R<sup>a1</sup>, R<sup>a2</sup> and R<sup>a3</sup>, which may be the same as or different from, respectively represent  
 a C<sub>1-6</sub> alkyl group or a C<sub>6-14</sub> aryl group), each of which may have a substituent);

(4) a halogen atom; or

(5) -R<sup>M</sup>.N.R<sup>N1</sup>R<sup>N2</sup>, (wherein R<sup>M</sup> represents a single bond or -O-CO-; and R<sup>N1</sup> and R<sup>N2</sup>

1) may be the same as or different from, respectively represent:

1-1) hydrogen atom; or  
 1-2)

(i) a C<sub>1-22</sub> alkyl group;  
 (ii) an unsaturated C<sub>2-22</sub> alkyl group;  
 (iii) a C<sub>2-22</sub> alkanoyl group;  
 (iv) a C<sub>7-15</sub> aroyl group;  
 (v) an unsaturated C<sub>3-23</sub> alkanoyl group;  
 (vi) a C<sub>6-14</sub> aryl group;  
 (vii) a 5-membered to 14-membered heteroaryl group;  
 (viii) a C<sub>7-22</sub> aralkyl group;  
 (ix) a C<sub>1-22</sub> alkylsulfonyl group; or  
 (x) a C<sub>6-14</sub> arylsulfonyl group, each of which may have a substituent, or

2) and R<sup>N1</sup> and R<sup>N2</sup> may be combined with the nitrogen atom to which they bound, to form a 3-membered to  
 14-membered nitrogen-containing non-aromatic heterocyclic group), provided that


R<sup>21a</sup> and R<sup>21b</sup> may be combined with each other to form (i) a ketone structure (=O) or (ii) an oxime structure  
 (=NOR<sup>2x</sup> (wherein R<sup>2x</sup> represents a C<sub>1-22</sub> alkyl group, an unsaturated C<sub>2-22</sub> alkyl group, a C<sub>6-14</sub> aryl group, a  
 5-membered to 14-membered heteroaryl group or a C<sub>7-22</sub> aralkyl group, each of which may have a substituent));  
 R<sup>16a</sup> represents hydrogen atom;  
 R<sup>21c</sup> represents:

(1) hydrogen atom; or  
 (2)




(wherein R<sup>22a</sup>, R<sup>22b</sup> and R<sup>22c</sup>, which may be the same as or different from, respectively represent:

1) hydrogen atom;  
 2) a C<sub>1-6</sub> alkyl group;  
 3) -OR (wherein R has the same meaning as the above);  
 4) -R<sup>M</sup>.N.R<sup>N1</sup>R<sup>N2</sup> (wherein R<sup>M</sup>, R<sup>N1</sup> and R<sup>N2</sup> have the same meanings as the above); or  
 5) a halogen atom, or any one of R<sup>21a</sup> and R<sup>21b</sup> may be combined with any one of R<sup>22a</sup> and  
 R<sup>22b</sup> to form the partial structure;



); and  $G^m$  represents:

(1) a group represented by the formula (GM-I):



(wherein

$R^2$  and  $R^{10}$ , which may be the same as or different from, respectively represent hydrogen atom or a  $C_{1-22}$  alkyl group;

$R^{5a}$ ,  $R^{5b}$ ,  $R^{6a}$ ,  $R^{6b}$  and  $R^{7b}$ , which may be the same as or different from, respectively represent:

- 1) hydrogen atom;
- 2) hydroxyl group;
- 3)

3-1) a  $C_{1-22}$  alkyl group;

3-2) a  $C_{1-22}$  alkoxy group;

3-3) a  $C_{6-14}$  aryloxy group;

3-4) a 5-membered to 14-membered heteroaryloxy group;

3-5) a  $C_{2-22}$  alkanoyloxy group;

3-6) a  $C_{7-15}$  aryloxy group;

3-7) a  $C_{3-22}$  unsaturated alkanoyloxy group;

3-8)  $-OCOR^{60}$  (wherein  $R^{60}$  has the same meaning as the above);

3-9) a  $C_{1-22}$  alkylsulfonyloxy group;

3-10) a  $C_{6-14}$  arylsulfonyloxy group; or

3-11)  $-OSIR^{51}R^{52}R^{53}$  (wherein  $R^{51}$ ,  $R^{52}$  and  $R^{53}$  have the same meanings as the above), each of which may have a substituent;

4) a halogen atom; or


5)  $-R^M.NR^{N1}R^{N2}$  (wherein  $R^M$ ,  $R^{N1}$  and  $R^{N2}$  have the same meanings as the above); or

$R^{5a}$  and  $R^{5b}$  may be combined with each other to form a ketone structure ( $=O$ ); or


$R^{6a}$  and  $R^{6b}$  may be combined with each other to form a spirooxysilanyl group or an exomethylene group; or

$R^{7a}$  and  $R^{7b}$ , which may be the same as or different from, respectively represent hydrogen atom or  $-OR^{I1}$  (wherein  $R^{I1}$  represents hydrogen atom, a  $C_{1-22}$  alkyl group or a  $C_{2-22}$  alkanoyl group));


(2) a group represented by the formula (GM-II):



15 (wherein  $R^2$ ,  $R^{3a}$ ,  $R^{3b}$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{7a}$ ,  $R^{7b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I));  
(3) a group represented by the formula (GM-III):




30 (wherein  $R^2$ ,  $R^{5a}$ ,  $R^{5b}$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{7a}$ ,  $R^{7b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I));  
(4) a group represented by the formula (GM-IV):




50 (wherein  $R^2$ ,  $R^{6a}$ ,  $R^{7a}$ ,  $R^{7b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I)); or  
(5) a group represented by the formula (GM-V):






wherein  $R^2$ ,  $R^{3a}$ ,  $R^{6a}$ ,  $R^{6b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-V)) during or after culturing, to convert it into a 16-position hydroxy macrolide compound represented by the formula (IV):



(wherein  $W$ ,  $R^{12}$ ,  $R^{16b}$ ,  $R^{17a}$ ,  $R^{17b}$ ,  $R^{20a}$ ,  $R^{20b}$ ,  $R^{21a}$ ,  $R^{21b}$ ,  $R^{21c}$  and  $G^m$  have the same meanings as those in the formula (III)); and then collecting the 16-position hydroxy macrolide compound thus converted;

(13) a production method according to (12), wherein the transformant is the transformant as described in (5) and has a DNA encoding ferredoxin;

(14) the production method as described in (12), the method comprises the step of converting a compound represented by the formula (III-a):




(wherein



represents a double bond or a single bond;  $W'$  represents a double bond or



; R<sup>5</sup> represents hydrogen atom or an acetoxy group; R<sup>6</sup> represents hydrogen atom or hydroxyl group; and R<sup>7</sup> represents hydrogen atom or acetyl group) into a compound represented by the formula (IV-a):



(wherein



(15) the production method as described in (14), wherein, in the conversion of the compound of the formula (III-a) into the compound of the formula (IV-a), the compound to be subjected is a compound selected from the group consisting of:

(1) a compound in which



Is a single bond; W' is



and R<sup>5'</sup>, R<sup>6'</sup> and R<sup>7'</sup> are respectively hydrogen atom;

(2) a compound in which



is a single bond,  $W'$  is



$R^5$  and  $R^6$  are respectively hydrogen atom; and  $R^7$  is acetyl group;

(3) a compound in which



is a single bond,  $W^*$  is



$R^5$  and  $R^7$  are respectively hydrogen atom; and  $R^6$  is hydroxyl group;

(4) a compound in which



is a single bond,  $W^*$  is



$R^5$  is hydrogen atom,  $R^6$  is hydroxy group; and  $R^7$  is acetyl group;

(5) a compound in which



is a single bond;  $W^*$  is a double bond; and  $R^5$ ,  $R^6$  and  $R^7$  are respectively hydrogen atom;

(6) a compound in which



is a single bond; W' is a double bond; R<sup>5'</sup> and R<sup>6'</sup> are respectively hydrogen atom; and R<sup>7'</sup> is acetyl group;

(7) a compound in which



is a single bond; W' is a double bond; R<sup>5'</sup> and R<sup>7'</sup> are respectively hydrogen atom; and R<sup>6'</sup> is hydroxyl group;

(8) a compound in which



is a single bond; W' is a double bond; R<sup>5'</sup> is hydrogen atom; R<sup>6'</sup> is hydroxy group; and R<sup>7'</sup> is acetyl group;

(9) a compound in which



is a double bond; W' is



R<sup>5'</sup> and R<sup>7'</sup> are respectively hydrogen atom; and R<sup>6'</sup> is hydroxyl group;

(10) a compound in which



is a double bond; W' is



R<sup>5'</sup> is hydrogen atom; R<sup>6'</sup> is hydroxy group; and R<sup>7'</sup> is acetyl group;

(11) a compound in which



is a single bond; W' is



R<sup>5</sup> is acetoxy group; R<sup>6</sup> is hydroxyl group; and R<sup>7</sup> is hydrogen atom; and

(12) a compound in which



is a single bond; W' is



R<sup>5</sup> is an acetoxy group; R<sup>6</sup> is hydroxyl group; and R<sup>7</sup> is acetyl group; and

(16) use of the transformant as described in (5) or (10) for producing a 16-position hydroxy macrolide compound.

[0006] The present invention made it possible to isolate a DNA encoding a protein having the enzymatic activity in hydroxylating the 16-position of a macrolide compound 11107B or ferredoxin and to determine its nucleotide sequence. Moreover, a plasmid carrying the DNA and a transformant into which the plasmid transformed were formed and a 16-position hydroxy macrolide compound could be produced using the transformant in an efficient manner.

[0007] Hereinafter, embodiments of the present invention will be explained in detail.

Microorganisms having the ability of converting a macrolide compound 11107B into a macrolide compound 11107D

[0008] In the present invention, a DNA encoding a protein having enzymatic activity in hydroxylating the 16-position or ferredoxin, partly or entirely can be isolated from the mycelia isolated from a culture broth in which microorganisms having the ability of converting the macrolide compound 11107B into the macrolide compound 11107D are cultured and the nucleotide sequence of the DNA can be determined. Then, a self-replicative or integrating replicative recombinant plasmid carrying the DNA is architecturally formed and a transformant is prepared using the plasmid.

[0009] The transformant thus prepared is cultured in the culture media and the proliferated transformant is brought into contact with the macrolide compound represented by the above formula (III) during or after culturing, to thereby convert the macrolide compound into the 16-position hydroxy macrolide compound represented by the formula (IV) and the converted 16-position hydroxy macrolide compound is collected, whereby the 16-position hydroxy macrolide compound can be obtained.

[0010] Any microorganisms having the ability of converting the macrolide compound 11107B into the macrolide compound 11107D may be used irrespective of the type of species and strain. Preferable examples of the microorganisms may include a Streptomyces sp. Mer-11107 or A-1544 strain and an unidentified Actinomyces A-1560 strain which were each isolated from soils.

[0011] It is to be noted that the Streptomyces sp. Mer-11107 was deposited as FERM P-18144 at the National Institute of BioScience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome Tsukuba-

shi, Ibaraki-ken 305-8566 Japan) as of December 19, 2000, and then transferred to International Deposit FERM BP-7812 at International Patent Organism Depository (IPOD) National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken 305-8566 Japan) as of November 27, 2001.

The A-1544 strain was deposited as **FERM P-18943** at International Patent Organism Depository National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken 305-8566 Japan) as of July 23, 2002, and then transferred to International Deposit FERM BP-8446 as of July 30, 2003, at International Patent Organism Depository (IPOD) National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken 305-8566 Japan). The A-1560 strain was deposited as FERM P-19585 at the National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan) as of November 13, 2003 and then transferred to International Deposit FERM BP-10102 as of August 19, 2004, at International Patent Organism Depository (IPOD) National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken 305-8566 Japan).

[0012] The taxonomical properties of the above strains are as follows.

(Taxonomical properties of the Mer-11107 strain)

(1) Morphological characteristics

[0013] Spirillies type aerial hyphae were extended from the vegetative hyphae. Spore chains consisting of about 10 to 20 cylindrical spores were formed at the end of the matured aerial hyphae. The size of the spores was about  $0.7 \times 1.0 \mu\text{m}$ , the surface of the spores was smooth, and specific organs such as sporangium, sclerotium and flagellum were not observed.

(2) Cultural characteristics on various media

[0014] Cultural characteristics of the strain after incubation at 28°C for two weeks on various media are shown as follows. The color tone is described by the color names and codes which are shown in the parentheses of Tressner's Color wheels.

1) Yeast extract-malt extract agar medium

The strain grew well, the aerial hyphae grew up on the surface, and light gray spores (Light gray; d) were observed. The reverse side of colony was Light melon yellow (3ea). Soluble pigment was not produced.

2) Oatmeal agar medium

The strain grew moderately, the aerial hyphae grew slightly on the surface, and gray spores (Gray; g) were observed. The reverse side of colony was Nude tan (4gc) or Putty (1 1/2ec). Soluble pigment was not produced.

3) Inorganic salts-starch agar medium

The strain grew well, the aerial hyphae grew up on the surface, and gray spores (Gray; e) were observed. The reverse side of colony was Fawn (4ig) or Gray (g). Soluble pigment was not produced.

4) Glycerol-asparagine agar medium

The strain grew well, the aerial hyphae grew up on the surface, and white spores (White; a) were observed. The reverse side of colony was Pearl pink (3ca). Soluble pigment was not produced.

5) Peptone-yeast extract-iron agar medium

The strain growth was bad, and the aerial hyphae did not grow on the surface. The reverse side of colony was Light melon yellow (3ea). Soluble pigment was not produced.

6) Tyrosine agar medium

The strain grew well, the aerial hyphae grew up on the surface, and white spores (White; a) were observed. The reverse side of colony was Pearl pink (3ca). Soluble pigment was not produced.

(3) Utilization of various carbon sources

[0015] Various carbon sources were added to Pridham-Gottlieb agar and incubated 28°C for 2 weeks. The growth of the strain is shown below.

1) L-arabinose ±

2) D-xylose ±

3) D-glucose +

4) D-fructose +

- 5) Sucrose +  
 6) Inositol +  
 7) L-rhamnose -  
 8) D-mannitol +  
 9) Raffinose +  
 (+ positive, ± slightly positive, - negative)

(4) Various physiological properties

10 [0016] Various physiological properties of the present strain are as follows.

- (a) Range of growth temperature (yeast extract-malt extract agar, incubation for 2 weeks): 12°C to 37°C  
 (b) Range of optimum growth temperature (yeast extract-malt extract agar, incubation for 2 weeks): 21°C to 33°C  
 (c) Liquefaction of gelatin (glucose-peptone-gelatin medium): negative  
 (d) Coagulation of milk (skim milk medium): negative  
 (e) Peptonization of milk (skim milk medium): negative  
 (f) Hydrolysis of starch (inorganic salts-starch agar): positive (g) Formation of melanoid pigment (peptone-yeast extract-iron agar): negative  
 (tyrosine agar): negative  
 (h) Production of hydrogen sulfide (peptone-yeast extract-iron agar): negative  
 (i) Reduction of nitrate (broth containing 0.1% potassium nitrate): negative  
 (j) Sodium chloride tolerance (yeast extract-malt extract agar, incubation for 2 weeks): grown at a salt content of 4% or less

25 (5) Chemotaxonomy

[0017] LL-diaminopimic acid and glycine were detected from the cell wall of the present strain.  
 (Taxonomical properties of the A-1544 strain)

30 (1) Morphological characteristics

[0018] Spira type aerial hyphae were extended from vegetative hyphae in this strain. Spore chains consisting of about 10 to 20 of cylindrical spores were formed at the end of the matured aerial hyphae. The size of the spores was about 1.0 x 1.2 to 1.4 µm, the surface of the spores was spiny, and specific organs such as sporangium, sclerotium and flagellum were not observed.

(2) Cultural characteristics on various media

40 [0019] Cultural characteristics of the strain after incubation at 28°C for two weeks on various media are shown in Table 1. The color tone is described by the color names and codes which are shown in the parentheses of Tresner's Color wheels.

Table 1

Medium	Growth	Aerial hyphae	Color of vegetative hyphae	Soluble pigment
Yeast extract -malt extract agar (ISP-2)	Good	Thick Silver gray (3fe)	Light melon yellow (3ea)	None
Oatmeal agar (ISP-3)	Good	Abundant Light gray to Silver gray (d to 3fe)	Light melon yellow (3ea)	None
Inorganic salts - starch agar (ISP-4)	Good	Abundant Silver gray (3fe)	Light melon yellow (3ea)	None
Glycerol - asparagine agar (ISP-5)	Good	Abundant Ashes (5fe)	Light melon yellow (3ea)	None
Peptone-yeast extract - iron agar (ISP-6)	Good	None	Light melon yellow (3ea)	Pale blackish brown

(continued)

Medium	Growth	Aerial hyphae	Color of vegetative hyphae	Soluble pigment
Tyrosine agar (ISP-7)	Good	Abundant Covert gray (2fe)	Light melon yellow (3ea)	None

## (3) Utilization of various carbon sources

[0020] Various carbon sources were added to Pridham-Gottlieb agar and incubated at 28°C for 2 weeks. The growth of the strain is shown in Table 2.

Table 2

D-glucose	+	inositol	-
L-arabinose	+	L-rhamnose	+
D-xylose	+	D-mannitol	+
D-fructose	+	raffinose	-
sucrose	-		
+: positive, ±: slightly positive, -: negative			

## (4) Various physiological properties

[0021] Various physiological properties of the present strain are as follows.

- (a) Range of growth temperature (yeast extract-malt extract agar, incubation for 2 weeks): 15°C to 41°C
- (b) Range of optimum growth temperature (yeast extract-malt extract agar, incubation for 2 weeks): 20°C to 37°C
- (c) Liquefaction of gelatin (glucose-peptone-gelatin medium): positive
- (d) Coagulation of milk (skim milk medium): positive
- (e) Peptonization of milk (skim milk medium): positive
- (f) Hydrolysis of starch (inorganic salts-starch agar): positive
- (g) Formation of melanoid pigment (peptone-yeast extract-iron agar): positive (tyrosine agar): negative
- (h) Production of hydrogen sulfide (peptone-yeast extract-iron agar): positive
- (i) Reduction of nitrate (broth containing 0.1% potassium nitrate): negative
- (j) Sodium chloride tolerance (yeast extract-malt extract agar, incubation for 2 weeks): grown at a salt content of 7% or less

## (5) Chemotaxonomy

[0022] LL-diaminopimelic acid was detected from the cell wall of the present strain.

## DNA of the present invention

[0023] The present inventors have isolated a DNA participating in the hydroxylation of the 16-position of a macrolide compound, specifically, a DNA encoding a protein having 16-position hydroxylating enzymatic activity and a DNA encoding a protein having a ferredoxin function from the above microorganisms and determined the nucleotide sequence of the DNA. The DNA encoding a protein having 16-position hydroxylating enzymatic activity and the DNA encoding a protein having a ferredoxin function are hereinafter generically called "a 16-position hydroxylating enzyme relevant DNA" as the case may be.

[0024] The DNA encoding a protein having 16-position hydroxylating enzymatic activity is those represented by the following (1-1), (1-2) or (1-3):

- (1-1) a DNA selected from those having a continuous nucleotide sequence from the base 1322 to base 2548 of the sequence No. 1, a continuous nucleotide sequence from the base 420 to base 1604 of the sequence No. 2 and a



continuous nucleotide sequence from the base 172 to base 1383 of the sequence No. 3;  
 (1-2) a DNA which is a variant of the DNA described in the above (1-1);

- (i) is hybridized with any one of the DNAs described in the above (1-1) under a stringent condition; and  
 (ii) codes a protein having enzymatic activity in hydroxylating the 16-position of the macrolide compound; and

(1-3) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA described in the above (1-1) or (1-2) though it is not hybridized with any of the DNA described in the above (1-1) or (1-2) under a stringent condition because of the degeneracy of a gene codon.

**[0025]** The "16-position hydroxylating enzymatic activity" means such enzymatic activity as to hydroxylate the 16-position of the macrolide compound 11107B represented by the formula (I) to thereby convert the macrolide compound into the macrolide compound 11107D represented by the formula (II).

**[0026]** The DNA encoding a protein having a ferredoxin function in the present invention is those represented by the following (2-1), (2-2) or (2-3).

(2-1) a DNA encoding ferredoxin and selected from the group consisting of a continuous nucleotide sequence from the base 2564 to base 2761 of the sequence No. 1, a continuous nucleotide sequence from the base 1643 to base 1834 of the sequence No. 2 and a continuous nucleotide sequence from the base 1399 to base 1593 of the sequence No. 3;

(2-2) a DNA which is a variant of the DNA described in the above (2-1);

- (i) is hybridized with the DNA described in the above (2-1) under a stringent condition; and  
 (ii) codes a protein having a ferredoxin function; and

(2-3) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA represented by the above (2-1) or (2-2) though it is not hybridized with the DNA represented by the above (2-1) under a stringent condition because of the degeneracy of a gene codon.

**[0027]** "The ferredoxin function" means the protein function of transferring electrons to the above 16-position hydroxylating enzyme to bear a role together with the above 16-position hydroxylating enzyme in the hydroxylation reaction.

**[0028]** Also, "the nucleotide sequence hybridized under a stringent condition" means a DNA nucleotide sequence obtained when any one of the DNAs of the above (1-1) and (1-2) is used as a probe and, for example, a colony hybridization method, plaque hybridization method or Southern blot hybridization method is used. Examples of the DNA having such a nucleotide sequence may include those identified by carrying out hybridization in the presence of 0.7 to 1.0 M NaCl at 65°C using a filter to which a DNA derived from a colony or a plaque or a fragment of the DNA is fixed and then washing the filter at 65°C by using 0.1 to 2 × SSC solution (1 × SSC solution: 150 mM sodium chloride and 15 mM sodium citrate). The hybridization may be carried out according to the method described in Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., 1989 (hereinafter abbreviated as molecular cloning, 2nd ed.).

**[0029]** Examples of the DNA hybridized in a stringent condition include DNAs having a nucleotide sequence having a certain level or more of homology with the nucleotide sequence of the DNA to be used as the probe, and specifically DNAs having a nucleotide sequence having 80% or more, preferably 85% or more, more preferably 90% or more, still more preferably 95% or more and most preferably 98% or more homology with the nucleotide sequence of the DNA used as the probe.

**[0030]** There is no particular limitation to a method of obtaining the 16-position hydroxylating enzyme relevant DNA. An appropriate probe or a primer is prepared based on the information of the nucleotide sequence described in the sequence No. 1, No. 2 or No. 3 of the sequence chart in this specification. Using the probe or primer, a DNA library of microorganisms belonging to Actinomycetes is screened, and thus the DNA of the present invention can be isolated. The DNA library can be produced by the usual method from microorganisms expressing the aforementioned 16-position hydroxylating enzymatic activity.

**[0031]** The 16-position hydroxylating enzyme relevant DNA of the present invention can also be obtained by a PCR method. A DNA library derived from the aforementioned microorganisms is used as a template and a pair of primers which are so designed as to amplify any one of the nucleotide sequences described in the sequence No. 1, No. 2 or No. 3 are used to carry out PCR. The reaction condition of the PCR may be appropriately designed. Examples of the reaction condition may include the condition of a process in which the cycle of the process involving a reaction run at 94°C for 30 seconds (denaturing), a reaction run at 55°C for 30 seconds to one minute (annealing) and a reaction run at 72°C for 2 minutes (extension) is repeated 30 times and then a reaction is run at 72°C for 7 minutes. Then, the

amplified DNA fragment can be cloned in a vector which can be amplified in a proper host.

[0032] The aforementioned operations such as the preparation of a probe or a primer, the construction of a DNA library, the screening of a DNA library and the cloning of a target gene are obvious to a person skilled in the art and may be carried out according to methods as described in for example, Molecular Cloning 2nd ed., Current Protocols in Molecular Biology, Supplement 1 to 38, John Wiley & Sons (1987-1997).

[0033] No particular limitation is imposed on a method of obtaining the protein in the present invention. The protein may be a protein synthesized by chemical synthesis or a recombinant protein produced by gene recombination techniques. When the recombinant protein is produced, first, the DNA encoding the protein as described above in this specification is obtained. The protein of the present invention can be produced by introducing this DNA into a proper expression system. Manifestation of the protein in the expression system will be described later in the specification.

Recombinant vector in the present invention

[0034] The DNA of the present invention may be used in the situation where it is inserted in an appropriate vector. No particular limitation is imposed on the kind of the vector to be used in the present invention and the vector may be either a self-replicative one (for example, a plasmid) or one that is incorporated into a genome of a host cell when introduced into the host cell and is replicated together with the incorporated chromosome. In the expression vector, the DNA of the present invention is operationally linked to elements (for example, a promoter) which are necessary for transcription. The promoter is a DNA sequence exhibiting transcriptional activity in a host cell and may be selected suitably corresponding to the type of host.

The transformant of the present invention and production of a recombinant protein using the transformant

[0035] The transformant may be produced by introducing the DNA or recombinant vector of the present invention into an appropriate host. The host cell into which the DNA or recombinant vector of the present invention is introduced may be any desired cell which can express the gene according to the present invention. Examples of the host cell include bacteria, yeast, fungi and higher eucaryotic cells. Examples of the bacterial cell include Gram-positive bacteria such as *Bacillus* or *Streptomyces* or Gram-negative bacteria such as *E. coli*. The transformation of these bacteria may be accomplished using a competent cell according to a protoplast method, electroporation method or other known methods. For example, the electroporation method may be performed as follows. A plasmid into which a foreign gene is inserted is added to a suspension of the competent cell, this suspension is poured into a cuvet specially used for an electroporation method and high-voltage electric pulse is applied to the cuvet. Then, the cells are cultured in a selective medium and a transformant is isolated on a plate agar media.

[0036] Examples of the yeast cell include cells belonging to *Saccharomyces* or *Schizosaccharomyces*. Specific examples of the yeast cell include *Saccharomyces cerevisiae* or *Saccharomyces kluyveri*. Examples of a method of introducing the recombinant vector into the yeast host may include an electroporation method, spheroplast method and lithium acetate method. Examples of the above other fungus cell include mycotic cells belonging to *Aspergillus*, *Neurospora*, *Fusarium* or *Trichoderma*. When mold fungi are used as the host cell, a DNA architecture is incorporated into a host chromosome to obtain a recombinant host cell, whereby transformation can be accomplished. The incorporation of the DNA architecture into the host chromosome can be accomplished, for example, by homologous recombination or heterologous recombination.

[0037] The above transformant is cultured in an appropriate nutrient medium under the condition enabling the expression of the introduced gene. In order to isolate the protein of the invention from the culture product of the transformant and to purify the protein, the usual protein isolating and purifying method may be used.

[0038] For example, when the protein of the present invention is expressed in a soluble form in cells, the cells are collected by centrifugation after the cultivation is finished and are suspended in a buffer solution. Then, the suspended solution is subjected to, for example, an ultrasonic crusher to break the cells, thereby obtaining a cell-free extract and the cell-free extract is centrifuged. A purified preparation can be obtained from the obtained supernatant by combining measures such as the usual isolation and purifying methods such as a solvent extraction method, salting-out method using ammonium sulfate, desalting method, precipitation method using organic solvent, anion exchange chromatography using a resin such as diethylaminoethyl (DEAE) sepharose, cation exchange chromatography using a resin such as SP-Sephacrose FF (manufactured by Amasham Bioscience Company), hydrophobic chromatography using a resin such as butyl sepharose and phenyl sepharose, gel filtration method using a molecular sieve, affinity chromatography, chromatofocusing method and electrophoresis method such as an isoelectric focusing electrophoresis.

Method of production of 16-position hydroxy macrolide compounds

[0039] The present invention involves a method of producing 16-position hydroxy macrolide compounds represented by the above formula (IV), the method comprising using a transformant into which a DNA encoding a protein having 16-position hydroxylating enzymatic activity or a protein having a ferredoxin function is introduced and hydroxylating mac-

police compounds represented by the above formula (III) in the presence of the transformant.

**[0040]** The macrolide compounds that can be hydroxylated by the transformant of the present invention is macrolide compounds represented by the above formula (III) (macrolide compounds represented by the above formula (IV)), preferably macrolide compounds represented by the above formula (III-a) (macrolide compounds represented by the above formula (IV-a) and more preferably the macrolide compound 11107B (macrolide compound 11107D). The compounds in the parenthesis are 16-position hydroxy macrolide compounds that are hydroxylated products.

**[0041]** The condition under which the macrolide compounds are hydroxylated in the presence of the transformant is as follows.

**[0042]** First, the 16-position hydroxylating enzyme relevant DNA in the transformant is expressed by adding, if necessary, inducing materials. The strain expressing the DNA is brought into contact with the macrolide compounds represented by the above formula (III) to run a conversion reaction. The temperature of the conversion reaction may be suitably determined taking the optimum growth temperature of the transformant into account. The reaction time may also be suitably determined in consideration of the conversion rate (degree of progress of the reaction) into the 16-position hydroxy macrolide compound. For example, the condition of 20 to 31°C and 1 to 5 days is preferable. Moreover, as to the reaction system, the reaction may be run in any system including a batch system or a continuous system.

**[0043]** For the isolation and purifying of the produced 16-position hydroxymacrolide compounds, the separation and purifying method used usually to isolate a microbial metabolite from the culture broth may be utilized. All known separation and purifying methods such as organic solvent extraction using methanol, ethanol, acetone, butanol, ethyl acetate, butyl acetate, chloroform or toluene, absorption chromatography using a hydrophobic adhesive resin such as Diaion HP-20, gel filtration chromatography using Setadex LH-20, adsorption chromatography using activated carbon, silica gel or the like, absorption chromatography using thin-layer chromatography and high-performance liquid chromatography using an reverse phase column are equivalent to these separation and purifying methods. The separation and purifying method is not limited to these methods shown here. These methods may be used singly or in combinations of two or more in an optional order or repeatedly, which makes it possible to isolate and purify the target 16-position hydroxy macrolide compounds.

**[0044]** The variant of the DNA in the present invention means a DNA that is obtained by modifying the DNA by deletion, conversion, addition or insertion treatments in the structural base of the DNA or its derivatives and shows the same effects as the original DNA.

**[0045]** The "halogen atom" used in the specification of the present application means a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.

**[0046]** The "C<sub>1-22</sub> alkyl group" used in the specification of the present application indicates a linear or branched alkyl group having 1 to 22 carbon atoms, such as methyl group, ethyl group, n-propyl group, iso-propyl group, n-butyl group, iso-butyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, n-hexyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 1-ethylbutyl group, 2-ethylbutyl group, 2-methylpentyl group, 3-methylpentyl group, n-heptyl group, n-octyl group, n-nonyl group or n-decyl group; preferably a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl group, ethyl group, n-propyl group, iso-propyl group, n-butyl group, iso-butyl group, sec-butyl group or tert-butyl group.

**[0047]** The "unsaturated C<sub>2-22</sub> alkyl group" used in the specification of the present application indicates a linear or branched alkenyl group having 2 to 22 carbon atoms or a linear or branched alkynyl group having 2 to 22 carbon atoms, such as vinyl group, allyl group, 1-propenyl group, isopropenyl group, 2-methyl-1-propenyl group, 1-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 1-hexenyl group, 1,3-hexadienyl group, 1,5-hexadienyl group, ethynyl group, 1-propynyl group, 2-propynyl group, 1-butylnyl group, 2-butylnyl group, 3-butylnyl group, 1-ethynyl-2-propynyl group, 2-methyl-2-propynyl group, 1-pentylnyl group, 1-hexynyl group, 1,3-hexadienylnyl group or 1,5-hexadienylnyl group. It preferably indicates a linear or branched alkenyl group having 2 to 10 carbon atoms or a linear or branched alkynyl group having 2 to 10 carbon atoms, such as vinyl group, allyl group, 1-propenyl group, isopropenyl group, ethynyl group, 1-propynyl group, 2-propynyl group, 1-butylnyl group, 2-butylnyl group or 3-butylnyl group.

**[0048]** The "C<sub>6-14</sub> aryl group" used in the specification of the present application means an aromatic hydrocarbon group having 6 to 14 carbon atoms, and a monocyclic group and condensed rings such as a bicyclic group and a tricyclic group are included. Examples thereof are phenyl group, indenyl group, 1-naphthyl group, 2-naphthyl group, azulenylnyl group, heptalenyl group, indacenyl group, acenaphthyl group, fluorenylnyl group, phenalenyl group, phenanthrenyl group and anthracenyl group; of which a preferred example is phenyl group, 1-naphthyl group or 2-naphthyl group.

**[0049]** The "5-membered to 14-membered heteroaryl group" used in the specification of the present application means a monocyclic, bicyclic or tricyclic 5-membered to 14-membered aromatic heterocyclic group which contains one or more of hetero atoms selected from the group consisting of a nitrogen atom, sulfur atom and oxygen atom. Preferred examples thereof are a nitrogen-containing aromatic heterocyclic group such as pyrrolyl group, pyridinyl group, pyridazinyl group,

pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isindolyl group, indolizyl group, purinyl group, indazolyl group, quinolizyl group, isoquinolizyl group, quinolizyl group, phthalazinyl group, naphthyridinyl group, quinoxalinyl group, quinoxalinyl group, cinnolizyl group, pteridinyl group, imidazotriazinyl group, pyrazinopyridazinyl group, acridinyl group, phenanthridinyl group, carbazolyl group, carbazolinyl group, perimidinyl group, phenanthrolinyl group, phenazinyl group, imidazo-pyridinyl group, imidazopyrimidinyl group, pyrazolopyridinyl group or pyrazolopyridinyl group; a sulfur-containing aromatic heterocyclic group such as thienyl group or benzothenyl group; and an oxygen-containing aromatic heterocyclic group such as furyl group, pyranyl group, cyclopentapyranyl group, benzofuryl group or isobenzofuryl group; an aromatic heterocyclic group containing two or more different hetero atoms, such as thiazolyl group, isothiazolyl group, benzothiazolyl group, benzothiadiazolyl group, phenothiazinyl group, isoxazolyl group, furazanyl group, phenoxazinyl group, oxazolyl group, isoxazolyl group, benzoxazolyl group, oxadiazolyl group, pyrazoloisoxazolyl group, imidazothiazolyl group, thienofuranyl group, furofuryl group or pyridoxazinyl group, of which a preferred example is thienyl group, furyl group, pyridinyl group, pyridazinyl group, pyrimidinyl group or pyrazinyl group.

[0050] The "3-membered to 14-membered nitrogen-containing non-aromatic heterocyclic group" used in the specification of the present application means a monocyclic, bicyclic or tricyclic 3-membered to 14-membered non-aromatic heterocyclic group containing one or more nitrogen atoms. Preferable examples thereof include an azolidinyl group, azetizyl group, pyrrolidinyl group, pyrrolidyl group, piperidinyl group, piperazinyl group, homopiperidinyl group, homopiperazinyl group, imidazolyl group, pyrazolidinyl group, imidazolidinyl group, morpholinyl group, thiomorpholinyl group, imidazolinyl group, oxazolinyl group and quinuclidinyl group. The nitrogen-containing non-aromatic heterocyclic group also includes a group derived from a pyridone ring and a non-aromatic condensed ring (such as a group derived from a phthalimide ring or succinimide ring).

[0051] The " $C_{2-22}$  alkanoyl group" used in the specification of the present application means a group corresponding to the above-defined " $C_{1-22}$  alkyl group" in which the end thereof is a carbonyl group. Examples thereof include acetyl group, propionyl group, butyryl group, iso-butyryl group, valeryl group, iso-valeryl group, pivalyl group, caproyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearyl group and arachidoyl group. Preferable examples thereof include alkanoyl groups having 2 to 6 carbon atoms such as acetyl-group, propionyl group, butyryl group or iso-butyryl group.

[0052] The " $C_{7-15}$  aryl group" used in the specification of the present application means a group corresponding to the above-defined " $C_{6-14}$  aryl group" or "5-membered to 14-membered heteroaryl group" to each of which end a carbonyl group is bonded. Examples thereof include benzoyl group, 1-naphthoyl group, 2-naphthoyl group, picolinoyl group, nicotinoyl group, isonicotinoyl group and furoyl group.

[0053] The " $C_{3-23}$  unsaturated alkanoyl group" used in the specification of the present application means a group corresponding to the above-defined "unsaturated  $C_{2-22}$  alkyl group" to which end a carbonyl group is bonded. Examples thereof include an acryloyl group, propioloyl group, crotonoyl group, iso-crotonoyl group, oleoyl group and linolenoyl group. Preferable examples thereof include unsaturated alkanoyl groups having 2 to 6 carbon atoms and specifically an acryloyl group.

[0054] The " $C_{7-22}$  aralkyl group" used in the specification of the present application means a group corresponding to the above-defined " $C_{1-22}$  alkyl group" of which substitutable moiety is replaced by the above-defined " $C_{6-14}$  aryl group" and being constituted of 7 to 22 carbon atoms. Specific examples thereof are benzyl group, phenethyl group, 3-phenyl-propyl group, 4-phenylbutyl group, 1-naphthylmethyl group and 2-naphthylmethyl group, of which an aralkyl group having 7 to 10 carbon atoms such as benzyl group or phenethyl group is preferred.

[0055] The " $C_{1-22}$  alkoxy group" used in the specification of the present application means a group corresponding to the above-defined " $C_{1-22}$  alkyl group" to which end an oxygen atom is bonded. Suitable examples thereof are methoxy group, ethoxy group, n-propoxy group, iso-propoxy group, n-butoxy group, iso-butoxy group, sec-butoxy group, tert-butoxy group, n-pentyloxy group, iso-pentyloxy group, sec-pentyloxy group, n-hexyloxy group, iso-hexyloxy group, 1,1-dimethylpropoxy group, 1,2-dimethylpropoxy group, 2,2-dimethylpropoxy group, 2-ethylpropoxy group, 1-ethyl-2-methylpropoxy group, 1,1,2-trimethylpropoxy group, 1,2,2-trimethylpropoxy group, 1,1-dimethylbutoxy group, 1,2-dimethylbutoxy group, 2,2-dimethylbutoxy group, 2,3-dimethylbutoxy group, 1,3-dimethylbutoxy group, 2-ethylbutoxy group, 1,3-dimethylbutoxy group, 2-methylpentyloxy group, 3-methylpentyloxy group and hexyloxy group.

[0056] The "unsaturated  $C_{2-22}$  alkoxy group" used in the specification of the present application means a group corresponding to the above-defined "unsaturated  $C_{2-22}$  alkyl group" to which end an oxygen atom is bonded. Suitable examples thereof are vinyloxy group, allyloxy group, 1-propenyloxy group, isopropenyloxy group, 2-methyl-1-propenyloxy group, 2-methyl-2-propenyloxy group, 1-butenyloxy group, 2-butenyloxy group, 3-butenyloxy group, 1-pentyloxy group, 1-hexenyloxy group, 1,3-hexadienyloxy group, 1,5-hexadienyloxy group, propargyloxy group and 2-butyloxyloxy group.

[0057] The " $C_{6-14}$  aryloxy group" used in the specification of the present application means a group corresponding to the above-defined " $C_{6-14}$  aryl group" to which end an oxygen atom is bonded. Specific examples thereof are phenoxy group, indenyloxy group, 1-naphthyloxy group, 2-naphthyloxy group, azulenyloxy group, heptalenyloxy group, indace-

nyloxy group, acenaphthoxy group, fluorenyloxy group, phenalenyloxy group, phenanthrenyloxy group and anthracenyloxy group.

[0058] The "5-membered to 14-membered heteroaryloxy group" used in the specification of the present application means a group corresponding to the above-defined "5-membered to 14-membered heteroaryl group" to which an oxygen atom is bonded. Specific examples thereof are pyrolyloxy group, pyridinyloxy group, pyridazinyloxy group, pyrimidinyloxy group, pyrazinyloxy group, triazolyloxy group, tetrazolyloxy group, benzotriazolyloxy group, pyrazolyloxy group, imidazolyloxy group, benzimidazolyloxy group, indolyloxy group, isoindolyloxy group, indolizinyloxy group, purinyloxy group, indazolyloxy group, quinolinyloxy group, isoquinolinyloxy group, quinolizinyloxy group, phthalazinyloxy group, naphthyridinyloxy group, quinoxalinyloxy group, quinazolinyl group, cinnolinyloxy group, pteridinyloxy group, imidazotriazinyloxy group, pyrazinopyridazinyloxy group, acridinyloxy group, phenanthridinyloxy group, carbazolyloxy group, carbazotriazolyloxy group, penimidinyloxy group, phenanthrolinyloxy group, phenazinyloxy group, imidazopyridinyloxy group, imidazo-pyrimidinyloxy group, pyrazolopyridinyloxy group, pyrazolopyridinyloxy group, thienyloxy group, benzothienyloxy group, furyloxy group, pyranoyloxy group, cyclopentapyranoyloxy group, benzofuryloxy group, isobenzofuryloxy group, thiazolyloxy group, isothiazolyloxy group, benzothiazolyloxy group, benzothiadiazolyloxy group, phenothiazinyloxy group, isoxazolyloxy group, furazanyloxy group, phenoxazinyloxy group, oxazolyloxy group, isoxazolyloxy group, benzoxazolyloxy group, oxadiazolyloxy group, pyrazolooxazolyloxy group, imidazothiazolyloxy group, thienofuranyloxy group, furopyrrolyloxy group and pyridoxazinyloxy group, of which a preferred example is thienyloxy group, furyloxy group, pyridyloxy group, pyridazyloxy group, pyrimidyloxy group or pyrazolyloxy group.

[0059] The "5-membered to 14-membered heteroaryloxyalkyl group" used in the specification of the present application means a group corresponding to the above-defined "C<sub>1-6</sub> alkyl group" which is substituted with the above-defined "5-membered to 14-membered heteroaryloxy group".

[0060] The "C<sub>1-22</sub> alkylsulfonyl group" used in the specification of the present application means a sulfonyl group to which the above-defined "C<sub>1-22</sub> alkyl group" is bound. Specific examples thereof are methanesulfonyl group, ethanesulfonyl group, n-propanesulfonyl group and iso-propanesulfonyl group.

[0061] The "C<sub>6-14</sub> arylsulfonyl group" used in the specification of the present application means a sulfonyl group to which the above-defined "C<sub>6-14</sub> aryl group" is bound. Specific examples thereof are benzenesulfonyl group, 1-naphthalenesulfonyl group and 2-naphthalenesulfonyl group.

[0062] The "C<sub>1-22</sub> alkylsulfonyloxy group" used in the specification of the present application means a group corresponding to the above-defined "C<sub>1-22</sub> alkylsulfonyl group" to which an oxygen atom is bonded. Examples thereof are methylsulfonyloxy group, ethylsulfonyloxy group, n-propylsulfonyloxy group and iso-propylsulfonyloxy group.

[0063] Examples of the substituent in the term "may have a substituent" used in the specification of the present application include those selected from the group consisting of:

- (1) halogen atom;
- (2) hydroxyl group;
- (3) thiol group;
- (4) nitro group;
- (5) nitroso group;
- (6) cyano group;
- (7) carbonyl group;
- (8) sulfonyloxy group;
- (9) amino group;
- (10) a C<sub>1-22</sub> alkyl group (for example, methyl group, ethyl group, n-propyl group, iso-propyl group, n-butyl group, iso-butyl group, sec-butyl group and tert-butyl group);
- (11) an unsaturated C<sub>2-22</sub> alkyl group (for example, vinyl group, allyl group, 1-propenyl group, isopropenyl group, ethynyl group, 1-propynyl group, 2-propynyl group, 1-butylnyl group, 2-butylnyl group and 3-butylnyl group);
- (12) a C<sub>6-14</sub> aryl group (for example, phenyl group, 1-naphthyl group and 2-naphthyl group);
- (13) a 5-membered to 14-membered heteroaryl group (for example, thienyl group, furyl group, pyridinyl group, pyridazinyl group, pyrimidinyl group and pyrazinyl group);
- (14) a 3-membered to 14-membered nitrogen-containing non-aromatic heterocyclic group (for example, aziridinyl group, azetidyl group, pyrrolidinyl group, pyrrolyl group, piperidinyl group, piperazinyl group, imidazolidinyl group, pyrazolidinyl group, imidazolidinyl group, morpholinyl group, imidazolinyl group, oxazolinyl group and quinuclidinyl group);
- (15) a C<sub>1-22</sub> alkoxy group (for example, methoxy group, ethoxy group, n-propoxy group, iso-propoxy group, sec-propoxy group, n-butoxy group, iso-butoxy group, sec-butoxy group and tert-butoxy group);
- (16) a C<sub>6-14</sub> aryloxy group (for example, phenoxy group, 1-naphthyloxy group and 2-naphthyloxy group);
- (17) a C<sub>7-22</sub> aralkyloxy group (for example, benzyloxy group, phenethyloxy group, 3-phenylpropyloxy group, 4-phenylbutyloxy group, 1-naphthylmethyloxy group and 2-naphthylmethyloxy group);
- (18) a 5-membered to 14-membered heteroaryloxy group (for example, thienyloxy group, furyloxy group, pyridinyloxy

group, pyridazinyloxy group, pyrimidinyloxy group and pyrazinyloxy group);

(19) a C<sub>2-23</sub> alkanoyl group (for example, acetyl group, propionyl group, butyryl group, iso-butyryl group, valeryl group, iso-valeryl group, pivalyl group, caproyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group and arachidoyl group);

(20) a C<sub>7-15</sub> aroyl group (for example, benzoyl group, 1-naphthoyl group and 2-naphthoyl group);

(21) a C<sub>3-23</sub> unsaturated alkanoyl group (for example, acryloyl group, propioloxy group, crotonoyl group, iso-crotonoyl group, oleoyl group and linolenoyl group);

(22) a C<sub>2-23</sub> alkanoyloxy group (for example, acetoxy group, propionyloxy group and acryloxy group);

(23) a C<sub>2-22</sub> alkoxy carbonyl group (for example, methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, iso-propoxycarbonyl group, n-butoxycarbonyl group, iso-butoxycarbonyl group, sec-butoxycarbonyl group and tert-butoxycarbonyl group);

(24) an unsaturated C<sub>3-22</sub> alkoxy carbonyl group (for example, vinylalkoxy carbonyl group, arylalkoxy carbonyl group, 1-propenyloxy carbonyl group, isopropenyloxy carbonyl group, propargyloxy carbonyl group and 2-butyloxy carbonyl group);

(25) a C<sub>1-22</sub> alkylsulfonyl group (for example, methanesulfonyl group, ethanesulfonyl group, n-propanesulfonyl group and iso-propanesulfonyl group);

(26) a C<sub>6-14</sub> arylsulfonyl group (for example, benzenesulfonyl group, 1-naphthalenesulfonyl group and 2-naphthalenesulfonyl group); and

(27) a C<sub>1-22</sub> alkylsulfonyloxy group (for example, methanesulfonyloxy group, ethanesulfonyloxy group, n-propanesulfonyloxy group and iso-propanesulfonyloxy group).

## Examples

### Reference Example 1 Production of starting material, a macrolide compound 11107B

[0064] One loopful of the slant culture (ISP-2 medium) of *Streptomyces* sp. Mer-11107 strain (FERM BP-7812) was inoculated into a 500 mL Erlenmeyer flask containing 50 mL of seed medium (2% of glucose, 1% of ESUSAN-MEAT manufactured by Ajinomoto Co. Ltd., 0.5% of yeast extract (manufactured by Oriental Yeast Co., Ltd.), 0.25% of sodium chloride, 0.32% of calcium carbonate, pH 6.8 before sterilization), and it was incubated at 28°C for two days to give the first seed culture broth. 0.1 mL of the culture broth was inoculated into a 500 mL Erlenmeyer flask containing 100 mL of the same seed medium and it was incubated at 28°C for one day to give the second seed culture broth. The second seed culture broth (800 mL) thus obtained was inoculated into a 200 L tank containing 100 L of a production medium (5% of soluble starch, 0.8% of Pharmamedia, 0.8% of gluten meal, 0.5% of yeast extract and 0.1% of calcium carbonate, pH 6.8 before sterilized) and it was cultured for five days with flowing air and stirring under the conditions of a culture temperature of 28°C, an agitation rotation of 90 rpm, a quantity of aeration of 1.0 vvm and an internal pressure of 20 kPa, to give a culture broth.

[0065] A part of the culture broth (10L) thus obtained was extracted with 10 L of 1-butanol, and then the resulting butanol layer was evaporated to dryness, to give 100 g of crude active fraction. The crude active fraction was applied on Sephadex LH-20 (1500 mL; manufactured by Pharmacia Co. Ltd.), and eluted with tetrahydrofuran-methanol (1:1) as a solvent. An eluted fraction from 540 mL to 660 mL was concentrated to dryness, to give a residue (660 mg). The resulting residue was dissolved in a mixture of ethyl acetate and methanol (9:1; v/v) and subjected to silica gel column chromatography (WAKO GEL C-200, 50 g). The column was eluted with a mixture (2 L) consisting of n-hexane and ethyl acetate (1:9, v/v), the fractions eluted from 468 mL to 1260 mL were collected, evaporated to give 25 mg of a crude active fraction.

[0066] The obtained crude active fraction was subjected to preparative high performance liquid chromatography (HPLC) under the following preparative HPLC condition (A), and the fractions eluted at the retention time of 34 minutes were collected. After removing acetonitrile, the respective fractions were desalted by HPLC under the following preparative HPLC condition (B) to give the macrolide compound 11107B (Retention time: 37 minutes, 6 mg).

### Preparative HPLC conditions A:

#### [0067]

Column:	YMC-PACK ODS-AM SH-343-5ÅM, φ20 mm × 250 mm (manufactured by YMC Co.)
Temperature:	room temperature
Flow rate:	10 mL/min.
Detection:	240 nm
Eluent:	acetonitrile/0.15% aqueous potassium dihydrogenphosphate (pH 3.5) (2:3 to 8:2, v/v, 0 to 50 min.,

linear gradient)

Preparative HPLC conditions B:

[0068]

Column: YMC-PACKODS-AMSH-343-5AM,  $\phi$ 20mm $\times$ 250mm (manufactured by YMC Co.)  
 Temperature: room temperature  
 Flow rate: 10 ml/min.  
 Detection: 240 nm  
 Eluent: methanol/water (2: 8 to 10: 0, v/v, 0 to 40 minutes, linear gradient)

Example 1 Determination of the nucleotide sequence of a gene derived from *Streptomyces* sp. A-1544 strain (FERM BP-8446) (1) Preparation of a DNA of *Streptomyces* sp. A-1544 strain chromosome

[0069] The A-1544 strain was inoculated into a medium containing 1% of glucose, 0.4% of malt extract and 1% of yeast extract and incubated at 28°C for 3 days. The obtained culture broth was centrifuged at 3000 rpm for 10 minutes to collect the mycelia. A chromosome DNA was prepared using Blood & Cell Culture kit (QIAGEN Co.) from the mycelia.

(2) Cloning of a partial sequence of a DNA encoding a protein having the activity in hydroxylating the 16-position of the macrolide compound 11107

[0070] Mix primers 5Dm-3F (sequence no. 4) and 5Dm-3R (sequence No. 5) were designed and produced on reference to the amino acid sequence assumed to be that of the cytochrome P450 (CYP105D5) of *Streptomyces coelicolor* A3 (2).

[0071] In order to promote reactivity taking the fluctuation of a codon into account, mixed bases S (=C+G) and Y (=C+T) were used.

[0072] Next, these two types of primers (5Dm-3F and 5Dm-3R) and the A-1544 strain chromosome DNA obtained in the above (1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a three-stage reaction including denaturing run at 98°C for 20 seconds, annealing run at 50°C for 2 minutes and extension run at 68°C for 30 seconds 35 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.). As a result, a DNA fragment (hereinafter referred to as a DNA fragment-A1) having a size of about 500 bp was amplified. It is highly possible that this DNA fragment-A1 is a part of the DNA encoding a protein having hydroxylating activity. The DNA fragment-A1 amplified by a PCR reaction was recovered from the reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.).

[0073] In order to obtain the DNA fragment-A1 in an amount enough to analyze the nucleotide sequence of the obtained DNA fragment-A1, the DNA fragment was combined with a plasmid vector pT7Blue T (Novagen Co.) by using DNA Ligation kit ver.2 (TAKARA HOLDINGS INC.) to transform *E. coli* JM109 strain. Thereafter, the transformed *E. coli* was selected using a L-broth agar media (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl, 1.5% agar) containing ampicillin (50  $\mu$ g/mL), X-gal (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside; 40  $\mu$ g/mL) and IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside; 100  $\mu$ M). The colony of the transformed *E. coli* thus isolated was cultured in a L-broth liquid medium (1% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing ampicillin (50  $\mu$ g/mL). A plasmid DNA was separated from the mycelia of the proliferated transformed *E. coli* and purified by using a plasmid purifying kit (QIA filter Plasmid Midi Kit, QIAGEN Co.), to obtain enough amount of the DNA fragment-A1.

(3) Analysis of the nucleotide sequence of the cloned DNA fragment-A1

[0074] The nucleotide sequence of the DNA fragment-A1 obtained in the above (2) was analyzed using a DNA nucleotide sequence analyzer (PE Bioystems 377XL) according to a dye terminator cycle sequence method. As the result of the nucleotide sequence analysis, it was clarified that the DNA fragment-A1 amplified by a PCR reaction had an exact size of 528 bp though it had been found to have a size of about 500 bp by the above measurement using electrophoresis (see the nucleotide sequence 1775 to nucleotide sequence 2302 of the sequence No. 1). Since DNA sequences corresponding to the two types of primers used in the above PCR reaction were found at both ends of the above cloned 528 bp DNA sequence, it was clarified that the DNA fragment-A1 was singularly amplified by these two types of primers (5Dm-3F and 5Dm-3R) in the above PCR reaction.

(4) Analysis of the neighboring region of the DNA fragment-A1

[0075] As mentioned above, the partial sequence of the DNA encoding a protein which was derived from the A-1544

strain and had hydroxylating activity. Therefore, the amplification, cloning and sequence analysis of the nucleotide sequence in the neighboring region extending from the upstream side to downstream side of the cloned fragment were accomplished by an inverse PCR method (Cell Technology vol. 14, p.591-593, 1995). Specifically, the A-1544 strain chromosome DNA (see the above (1)) was digested by respective restriction enzymes *Pst*I and *Sal*I in a H buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM dithiothreitol and 100 mM NaCl). The obtained each DNA fragment cut by the restriction enzymes was self-circularized by using DNA Ligation Kit ver.2 (TAKARA HOLDINGS INC.).

[0076] On the other hand, primers (6PIN-2F (sequence No. 6) and 6PIN-2R (sequence No. 7) were designed and produced based on the nucleotide sequence of the DNA fragment-A1.

[0077] Next, these two primers (6PIN-2F and 6PIN-2R) and the above self-cyclized A-1599 strain chromosome DNA as a template, were used to run a PCR reaction. In the PCR reaction, the cycle of a two-stage reaction involving denaturing run at 98°C for 20 seconds and annealing and extension run at 68°C for 5 minutes was repeated 35 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.).

[0078] As a result, a DNA fragment (DNA fragment-B1) about 3.5 kbp in size and a DNA fragment (DNA fragment-C1) about 2.8 kbp in size were amplified. It was highly possible that these DNA fragments were a DNA encoding a protein having hydroxylating activity and a DNA having a DNA sequence including the upstream and downstream regions of the former DNA.

[0079] The DNA fragment-B1 and the DNA fragment-C1 were recovered from the PCR amplified reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.). Next, as to the obtained DNA fragment-B1 and DNA fragment-C1, in order to obtain each DNA fragment in an amount enough to analyze the nucleotide sequence of the obtained DNA fragment, a plasmid vector pT7Blue T (Novagen Co.), DNA Ligation kit ver.2 (TAKARA HOLDINGS INC.), E. coli JM109 strain and a plasmid purifying kit (QIA filter Plasmid Midi kit, QIAGEN Co.) were used in the same manner as the above (2), to obtain enough amount of each DNA fragment.

(5) Analysis of each nucleotide sequence of the DNA fragment-B1 (about 3.5 kbp in size) and the DNA fragment-C1 (about 2.8 kbp in size)

[0080] Each nucleotide sequence of the DNA fragment-B1 and DNA fragment-C1 obtained in the above (4) was analyzed using a DNA nucleotide sequence analyzer (PE Biosystems 377XL) according to a dye terminator cycle sequence method. The nucleotide sequence was thus analyzed to obtain the information of the nucleotide sequence of 3793 bp shown in the sequence No. 1 from each sequence of the DNA fragment-B1 and DNA fragment-C1.

[0081] An open reading frame (ORF) in this 3793 bp was retrieved, to find that the two proteins were coded. Each amino acid sequence of these proteins was retrieved by the BLAST search, and as a result, an ORF (hereinafter referred to as *psmA*) coding a protein consisting of 409 amino acids having high homology to cytochrome P450 existed in the base 1322 to base 2548 of the sequence No. 1. The *psmA* had the highest homology (homology: 72.6%) to the amino acid sequence assumed to be that of cytochrome P450 (CYP105D5) of the *Streptomyces coelicolor* A3 (2) and to the amino acid sequence assumed to be that of cytochrome P450 (CYP105D4) of the *Streptomyces lividans*, and also had a relatively high homology (homology: 69.4%) to cytochrome P450 soy (Soy C) of *Streptomyces griseus*. It was considered from this fact that the *psmA* was highly possibly a gene coding hydroxylating enzyme of the cytochrome P-450 type.

[0082] Also, an ORF (hereinafter referred to as *psmB*) encoding a protein having a high homology to ferredoxin of a 3F-4S type existed just downstream (the base 2564 to base 2761 of the sequence No. 1) of the *psmA*. The protein encoded by the *psmB* consists of 66 amino acids, and had the highest homology (83.3%) to the amino acid sequence assumed to be that of ferredoxin just downstream of the amino acid sequence assumed to be that of cytochrome P450 (CYP105D5) of the *Streptomyces coelicolor* A3 (2) and a relatively higher homology (homology: 57.6%) to ferredoxin soy (soyB) of *Streptomyces griseus*. Therefore, it was considered that the *psmB* serves to transfer electrons and codes ferredoxin participating in hydroxylation together with the *psmA*. Example 2 Production of a transformant having the *psmA* and the *psmB*

(1) Preparation of a DNA fragment containing both the *psmA* and the *psmB* derived from the A-1544 strain

[0083] A primer DM-NdeF (sequence No. 8) obtained by adding a *Nde*I site to the 5' terminal and a primer DM-SpeR (sequence No. 9) obtained by adding a *Spe*I site to the 5' terminal were designed and produced on reference to the nucleotide sequence of the sequence No. 1 analyzed in Example 1. Next, these two types of primers (DM-NdeF and DM-SpeR) and the A-1544 strain chromosome DNA obtained in Example 1(1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a two-stage reaction including denaturing carried out at 98°C for 20 seconds and annealing and elongation carried out at 68°C for 2 minutes 30 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.).

[0084] As a result, a DNA fragment (hereinafter referred to as a DNA fragment-D1) having a size of about 1.5 kbp and containing the *psmA* and the *psmB* was amplified. The DNA fragment-D1 was recovered from this PCR amplified



reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.).

(2) Architecture of a plasmid pTC-DM



[0085] pT7NS-CamAB (see WO03/087381) was digested by respective restriction enzymes NdeI and SpeI in a H buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM dithiothreitol and 100 mM NaCl) to obtain a plasmid digested products. Similarly, the DNA fragment-D1 obtained in the above (1) was digested by respective restriction enzymes NdeI and SpeI. The obtained digested product of the DNA fragment-D1 and the plasmid digested product were coupled using DNA Ligation Kit ver.2 (TAKARA HOLDINGS INC.). This resulted in the formation of a plasmid (referred to as a plasmid pTC-DM) about 9.5 kbp in size which was an architecture of a combination of the DNA fragment-D1 containing both the psmA and the psmB therein and the plasmid pT7NS-CamAB.

(3) Preparation of E. coli transforming strain BL21 (DE3)/pTC-DM

[0086] Using the plasmid pTC-DM prepared in the above (2), a competent cell (Novagen) of Colibacillus BL21 (DE3) was transformed. E. coli BL21 (DE3) /pTC-DM strain transformed by the plasmid pTC-DM was obtained.

Example 3: Conversion of ME-265 into ME-282 represented by the following formulae by the E. coli transformant having the psmA and the psmB

[0087]



(1) Preparation of a transformant reaction solution

[0088] The transformed E. coli BL21 (DE3) /pTC-DM strain obtained in Example 2(3) and a frozen seed of a BL21 (DE3)/pT7NS-CamAB strain were inoculated into a 15 mL test tube containing 3 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing 50 µg/mL of ampicillin and shake-cultured at 37°C for 20 hours. 500

μL of the seed culture broth was inoculated into a 250 mL Erlenmeyer flask containing 50 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing 50 μg/mL of ampicillin and shake-cultured at 32°C for 3 hours. Then, 50 μL of 100 mM IPTG (isopropyl-β-D-thiogalactopyranoside) and 50 μL of 80 mg/mL 5-aminolevulinic acid were successively added thereto, and the medium was shake-cultured at 32°C for 6 hours. The obtained culture broth was centrifuged (5000 rpm, 10 minutes) to collect the mycelia. The mycelia were then suspended in 1.75 mL of a 100 mM phosphate buffer solution (pH 6.1), and 250 μL of 80% glycerol and 50 μL of 8 mg/mL ME-265 were added thereto. The conversion reaction solution thus obtained was reacted at 28°C for 24 hours. 200 μL of the reaction solution was extracted with 1 mL of acetonitrile and the extract was subjected to HPLC to measure each amount of ME-265 and ME-282. The results are shown in Table 3.

[0089] Also, the details of the condition of HPLC are shown below.

Analyzer: Shimadzu HPLC 10Avp

Column: CAPCELL PAK C18 SG120 (e4.6 mm x250 mm)

Mobile phase: 45% acetonitrile (0 to 15 minutes)

60% acetonitrile (15 to 30 minutes)

45% acetonitrile (30 to 45 minutes)

Flow rate: 1 mL/min.

Detection: UV 240 nm

Injection capacity: 10 μL

Column temperature: 40°C

Analyzing time: 45 minutes

Retention time: ME-265 24.8 minutes

ME-282 12.7 minutes

Table 3

mg/L	BL21(DE3)/pT7NS-CamAB	BL21(DE3)/pTC-DM
ME-265	143	0
ME-282	0	130

## (2) Isolation of ME-282 from the transformant reaction solution

[0090] 4 mL of water was added to 1.8 mL of the reaction solution that had been reacted for 24 hours and the reaction solution was then extracted with 8 mL of ethyl acetate once and with 4 mL of ethyl acetate twice. The ethyl acetate layers were combined, dried over anhydrous sodium sulfate and then the solvent was removed. The resulting residue was purified by thin layer chromatography (MERCK Silicagel 60 F254 0.25 mm, developing solution: hexane: ethyl acetate=1:2), to give 0.2 mg of ME-282.

[0091] <sup>1</sup>H-NMR spectrum (CD<sub>3</sub>OD, 500MHz): δ ppm (integral, multiplicity, coupling constant J(Hz)):

0.87(3H,d,J=7.0Hz), 0.90(3H,d,J=7.0Hz), 0.94(3H,t,J=7.3Hz), 0.97(3H,d,J=6.6Hz), 1.21-1.26(1H,m), 1.29-1.37(3H,m), 1.39(3H,s), 1.94-1.52(2H,m), 1.60-1.64(1H,m), 1.65(1H,dd,J=6.2,13.9Hz), 1.77(3H,d,J=1.1Hz), 1.86(1H,dd,J=5.4,13.9Hz), 1.89-1.99(1H,m), 2.00(3H,s), 2.43(1H,dd,J=5.5,13.9Hz), 2.50-2.60(1H,m), 2.56(1H,dd,J=3.3,13.9Hz), 2.66(1H,dd,J=2.7,7Hz), 2.89(1H,dt,J=2.6,2Hz), 3.52(1H,dt,J=4.8,8.4Hz), 3.75-3.80(1H,m), 4.90(1H,overlapped with D<sub>2</sub>O), 5.01(1H,d,J=10.6Hz), 5.42(1H,dd,J=9.2,15.0Hz), 6.13(1H,d,J=10.6Hz), 6.52(1H,dd,J=11.0,15.0Hz).

[0092] As a result, a peak estimated as that of ME-282 was not observed in the case of the E. coli BL21 (DE3)/pT7NS-CamAB strain used as a control, whereas ME-265 was almost consumed and a peak estimated as that of ME-282 was obtained in the case of the BL21 (DE3)/pTC-DM strain containing the psmA and psmB. This fact suggests that the psmA and the psmB participate in the conversion of ME-265 into ME-282.

Example 4: Conversion of the macrolide compound 11107B into the macrolide compound 11107D by the E. coli transformant having the psmA and the psmB

## (1) Preparation of a transformant reaction solution

[0093] A test using the macrolide compound 11107B as a substrate was made in the same manner as Example 3. The transformed E. coli BL21(DE3)/pTC-DM strain obtained in Example 2(3) and a frozen seed of a BL21 (DE3)/pT7NS-CamAB strain were inoculated into a 15 mL test tube containing 3 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5%NaCl) containing 50 μg/mL of ampicillin and shake-cultured at 30°C for 20 hours. 500 μL of the seed culture broth was inoculated into a 250 mL Erlenmeyer flask containing 50 mL of a L-broth medium (1.0% bactotripton,

0.5% yeast extract, 0.5% NaCl) containing 50 µg/mL of ampicillin and shake-cultured at 28°C for 5 hours. Then, 50 µL of 100 mM IPTG (isopropyl-β-D-thiogalactopyranoside) and 50 µL of 80mg/mL 5-aminolevulinic acid were successively added and the medium was shake-cultured at 25°C for 20 hours. The obtained culture broth was centrifuged (5000 rpm, 10 minutes) to collect the mycelia. The mycelia were then suspended in 1.75 mL of a 100 mM phosphate buffer solution (pH 6.1), and 250 µL of 80% glycerol and 50 µL of 40 mg/mL 11107B were added thereto. The conversion reaction solution thus obtained was reacted at 28°C for 24 hours. 200 µL of the reaction solution was extracted with 1 mL of acetonitrile and the extract was subjected to HPLC to measure each amount of the macrolide compound 11107B and the macrolide compound 11107D. The results are shown in Table 4. Also, the details of the condition of HPLC are shown below.

Analyzer: Shimadzu HPLC 10Avp  
 Column: CAPCELL PAK C18 SG120 (φ4.6 mm × 250 mm)  
 Mobile phase: 35% acetonitrile (0 to 10 minutes)  
 35% to 65% acetonitrile (10 to 12 minutes)  
 65% acetonitrile (12 to 15 minutes)  
 35% acetonitrile (15 to 20 minutes)  
 Flow rate: 1 mL/min.  
 Detection: UV 240 nm  
 Injection capacity: 10 µL  
 Column temperature: 40°C  
 Analyzing time: 20 minutes  
 Retention time: 11107B 14.3 minutes  
 11107D 7.9 minutes

Table 4

mg/L	BL21(DE3)pT7NS-CamAB	BL21(DE3)pTC-DM
11107B	636	619
11107D	0	71

(2) Isolation of the macrolide compound 11107D from the transformant reaction solution

**[0094]** 4 mL of water was added to 1.8 mL of the reaction solution that had been reacted for 24 hours and the mixture was then extracted with 8 mL of ethyl acetate once and with 4 mL of ethyl acetate twice. The ethyl acetate layers were combined, dried over anhydrous sodium sulfate and the solvent was removed. The resulting residue was purified by thin layer chromatography (MERCK Silicagel 60 F254 0.25 mm, developing solution: ethyl acetate) to obtain 0.1 mg of 11107D.

**[0095]** <sup>1</sup>H-NMR spectrum (CD<sub>3</sub>OD, 500MHz) : δ ppm (integral, multiplicity, coupling constant J(Hz)): 0.87(3H,d,J=7.0Hz), 0.88(3H,d,J=7.0Hz), 0.93(3H,t,J=7.0Hz), 1.18(3H,s), 1.18-1.69(8H,m), 1.33(3H,s), 1.77(3H,d,J=1.1Hz), 1.82-1.90(1H,m), 2.05(3H,s), 2.49-2.60(3H,m), 2.66(1H,dd,J=2.2,8.2Hz), 2.89(1H,dt,J=2.4,5.7Hz), 3.52(1H,dt,J=4.8,8.3Hz), 3.73-3.82(1H,m), 5.09(1H,d,J=9.8Hz), 5.05(1H,d,J=10.6Hz), 5.56(1H,dd,J=9.8,15.2Hz), 5.70(1H,dd,J=9.8,15.2Hz), 6.3(1H,d,J=10.8Hz), 6.52(1H,dd,J=10.8,15.2Hz).

**[0096]** As a result, a peak estimated as that of the macrolide compound 11107D was not observed in the case of the E. coli BL21 (DE3)/pT7NS-CamAB strain used as a control, whereas a peak estimated as that of the macrolide compound 11107D was obtained in the case of the BL21 (DE3)pTC-DM strain containing the psmA and psmB. This fact suggests that the psmA and the psmB participate in the conversion of macrolide compound 11107B into the macrolide compound 11107D.

Example 5: Conversion test using an A-1544 self-cloning strain

(1) Preparation of a DNA fragment containing both the psmA and the psmB derived from the A-1544 strain

**[0097]** A primer DM-BglIF (sequence No. 10) obtained by adding a BglII site to the 5' terminal and a primer DM-BglR (sequence No. 11) obtained by adding a BglII site to the 5' terminal were designed and produced on reference to the nucleotide sequence of the sequence No. 1 analyzed in Example 1.

**[0098]** Next, these two types of primers (DM-BglIF and DM-BglR) and the A-1544 strain chromosome DNA obtained in Example (1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a three-stage reaction including denaturing carried out at 98°C for 20 seconds, annealing carried out at 63°C for 30 seconds

and elongation carried out at 68°C for 4 minutes 30 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.).

[0099] As a result, a DNA fragment (hereinafter referred to as a DNA fragment-E1) having a size of about 3.5 kbp and containing the psmA and the psmB was amplified. This PCR amplified reaction solution was subjected to agarose gel electrophoresis to fractionate. The above DNA fragment-E1 about 3.5 kbp in size was cut out of the agarose gel and recovered by SUPREC 01 (TAKARA HOLDINGS INC.).

## (2) Architecture of a plasmid pJDMG

[1010] pJ702 was digested by a restriction enzyme BglII in a H buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM dithiothreitol and 100 mM NaCl) to obtain a plasmid digested products. Similarly, the DNA fragment-E1 obtained in the above (1) was digested by a restriction enzyme BglII. The obtained digested product of the DNA fragment-E1 and the plasmid-digested product were bound using DNA Ligation Kit ver.2 (TAKARA HOLDINGS INC.). The resulted in the formation of a plasmid (referred to as a plasmid pJDMG) about 8.5 kbp in size which was an architecture of a combination of the DNA fragment-E1 containing both the psmA and the psmB therein and the plasmid pJ702.

## (3) Preparation of a self-cloning strain A-1544/pJDMG strain

[1011] Using the plasmid pJDMG prepared in the above (2), an A-1544 strain was transformed according to the method described in Genetic Manipulation of Streptomyces: A Laboratory Manual, John Innes Foundation, Norwich, 1985. An A-1544/pJDMG strain was thus obtained by transformation using the plasmid pJDMG.

### Example 6: Conversion of 11107B into 11107D by a self-cloning strain

[1012] The transformed A-1544/pJDMG strain obtained in Example 5(3), A-1544/pJ702 strain and a frozen seed of the original A-1544 strain were inoculated into a 250 mL Erlenmeyer flask containing 50 mL of a SMN medium (Stabiose 2%, glucose 2%, ESUSAN-MEAT 2%, yeast extract 0.5%, NaCl 0.25%, CaCO<sub>3</sub> 0.32%, pH 7.4) containing 25 µg/mL of thiothrepton, and shake-cultured at 28°C for 48 hours (seed culture, no addition of thiothrepton to the A-1544 strain). 0.5 mL of the obtained seed culture broth was inoculated into a 250 mL Erlenmeyer flask containing 50 mL of a SMN medium containing 25 µg/mL of thiothrepton and shake-cultured at 28°C for 72 hours (no addition of thiothrepton to the A-1544 strain). The obtained culture broth was dispensed in 2 mL portions, and 100 µL of a 1M phosphate buffer solution (pH 6.5) and 50 µL of 40 mg/mL of 11107B were added thereto. The conversion culture broth thus obtained was reacted at 28°C for 12 hours. 200 µL of the reaction solution was extracted with 1 mL of acetonitrile and the extract was subjected to HPLC to measure each amount of 11107B and 11107D. The results are shown in Table 5. Also, the details of the condition of HPLC are shown below.

Analyzer: Shimadzu HPLC 10Avp  
Column: CAPCELL PAK C18 SG120 (4.6 mm x250 mm)  
Mobile phase: 35% acetonitrile (0 to 10 minutes)  
35% to 65% acetonitrile (10 to 12 minutes)  
65% acetonitrile (12 to 15 minutes)  
35% acetonitrile (15 to 20 minutes)  
Flow rate: 1 mL/min.  
Detection: UV 240 nm  
Injection capacity: 10 µL  
Column temperature: 40°C  
Analyzing time: 20 minutes  
Retention time: 11107B 14.3 minutes  
11107D 7.9 minutes

Table 5

mg/L	A-1544 strain	A-1544/pJ702 strain	A-1544/pJDMG strain
11107B	496	651	14
11107D	196	0	535

[1013] As a result, the A-1544/pJDMG strain obtained by transformation of the plasmid containing the psmA and the psmB exhibited conversion activity about 2.7 times that of the original A-1544 strain by a reaction run for 12 hours. This

fact suggests that the self-cloning of the *psmA* and *psmB* contributes to the conversion of the macrolide compound 11107B into the macrolide compound 11107D.

Example 7 Determination of the nucleotide sequence of a gene derived from *Streptomyces* sp. Mer-11107 strain (FERM BP-7812)

(1) Preparation of a DNA of *Streptomyces* sp. Mer-11107 strain chromosome

[0104] The Mer-11107 strain was inoculated into a medium containing 1% of glucose, 0.4% of malt extract and 1% of yeast extract and cultured at 28°C for 3 days. The obtained culture broth was centrifuged at 3000 rpm for 10 minutes to collect the mycelia. A chromosome DNA was prepared using Blood & Cell Culture kit (QIAGEN Co.) from the mycelia.

(2) Cloning of a partial sequence of a DNA encoding a protein having the activity in hydroxylating the 16-position of the macrolide compound 11107

[0105] Mix primers 5Dm-3F (sequence no. 4) and 5D-1R (sequence No. 12) were designed and produced on reference to the amino acid sequence estimated as that of the cytochrome P450 (CYP105D5) of *Streptomyces coelicolor* A3(2).

[0106] In order to promote reactivity taking the fluctuation of a codon into account, mixed bases S (=C+G) and Y (=C+T) were used.

[0107] Next, these two types of primers (5Dm-3F and 5D-1R) and the Mer-11107 strain chromosome DNA obtained in the above (1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a three-stage reaction including denaturing carried out at 98°C for 20 seconds, annealing carried out at 50°C for 2 minutes and elongation carried out at 68°C for 30 seconds 35 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.). As a result, a DNA fragment (hereinafter referred to as a DNA fragment-A2) having a size of about 300 bp was amplified. It is highly possible that the DNA fragment-A2 is a part of the DNA encoding a protein having hydroxylating activity. The DNA fragment-A2 amplified by a PCR reaction was recovered from the reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.).

[0108] In order to obtain the DNA fragment-A2 in an amount enough to analyze the nucleotide sequence of the obtained DNA fragment-A2, the DNA fragment was bound with a plasmid vector pT7Blue T (Novagen Co.) by using DNA Ligation kit ver.2 (TAKARA HOLDINGS INC.) to transform *E. coli* JM109 strain. Thereafter, the transformed *E. coli* was selected using a L-broth agar media (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl, 1.5% agar) containing ampicillin (50 µg/mL), X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside; 40 µg/mL) and IPTG (isopropyl-β-D-thiogalactopyranoside; 100 µM). The colony of the transformed *E. coli* thus isolated was cultured in a L-broth liquid medium (1% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing ampicillin (50 µg/mL). A plasmid DNA was separated from the mycelia of the proliferated transformed *E. coli* and purified by using a plasmid purifying kit (QIA filter Plasmid Midi Kit, QIAGEN Co.), to obtain enough amount of the DNA fragment-A2.

(3) Analysis of the nucleotide sequence of the cloned DNA fragment-A2

[0109] The nucleotide sequence of the DNA fragment-A2 obtained in the above (2) was analyzed using a DNA nucleotide sequence analyzer (PE Biosystems 377XL) according to a dye terminator cycle sequence method. As the result of the nucleotide sequence analysis, it was clarified that the DNA fragment-A2 amplified by a PCR reaction had an exact size of 325 bp though it had been found to have a size of about 300 bp by the above measurement using electrophoresis (see the nucleotide sequence 837 to nucleotide sequence 1161 of the sequence No. 2). Since DNA sequences corresponding to the two types of primers used in the above PCR reaction were found at both ends of the above cloned 325 bp DNA sequence, it was clarified that the DNA fragment-A2 was specifically amplified by these two types of primers (5Dm-3F and 5D-1R) in the above PCR reaction.

(4) Analysis of the neighboring region of the DNA fragment-A2

[0110] As mentioned above, the partial sequence of the DNA encoding a protein having the hydroxylating activity derived from the Mer-11107 strain was determined. Therefore, the amplification, cloning and sequence analysis of the nucleotide sequence in the neighboring region extending from the upstream side to downstream side of the cloned fragment were accomplished by an inverse PCR method (Cell Technology vol. 14, p.591-593, 1995).

Specifically, the Mer-11107 strain chromosome DNA (see the above (1)) was digested by a restriction enzyme BamHI in a K buffer solution (50 mM Tris-HCl, pH 8.5, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol and 100 mM KCl) and by a restriction enzyme SalI in a H buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol and 100 mM NaCl) respectively. The obtained each DNA fragment cut by the restriction enzymes was self-circularized using DNA Ligation

Kit ver.2 (TAKARA HOLDINGS INC.).

[0111] On the other hand, primers (7PIN-2F (sequence No. 13) and 6PIN-2R (sequence No. 7) were designed and produced based on the nucleotide sequence of the DNA fragment-A2.

[0112] Next, these two primers (7PIN-2F and 6PIN-2R) and the above self-circularized Mer-11107 strain chromosome DNA as a template, were used to run a PCR reaction. In the PCR reaction, the cycle of a two-stage reaction involving denaturing carried out at 98°C for 20 seconds and annealing and elongation carried out at 68°C for 5 minutes was repeated 35 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.).

[0113] As a result, a DNA fragment (DNA fragment-B2) about 1.3 kbp in size and a DNA fragment (DNA fragment-C2) about 1.4 kbp in size were amplified. It was highly possible that these DNA fragments were respectively a DNA encoding a protein having hydroxylating activity and a DNA having a DNA sequence including those in the upstream and downstream regions of the former DNA.

[0114] The DNA fragment-B2 and the DNA fragment-C2 were recovered from the PCR amplified reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.). Next, as to the obtained DNA fragment-B2 and DNA fragment-C2, in order to obtain each DNA fragment in an amount enough to analyze the nucleotide sequence of the obtained DNA fragment, a plasmid vector pT7Blue T (Novagen Co.), DNA Ligation kit ver.2 (TAKARA HOLDINGS INC.), E. coli JM109 strain and a plasmid purifying kit (QIA filter Plasmid Midi Kit, QIAGEN Co.) were used in the same manner as the above (2), to obtain enough amount of each DNA fragment.

(5) Analysis of each nucleotide sequence of the DNA fragment-B2 (about 1.3 kbp in size) and the DNA fragment-C2 (about 1.4 kbp in size)

[0115] Each nucleotide sequence of the DNA fragment-B2 and DNA fragment-C2 obtained in the above (4) was analyzed using a DNA nucleotide sequence analyzer (PE Biosystems 377XL) according to a dye terminator cycle sequence method. The nucleotide sequence was thus analyzed to obtain the information of the nucleotide sequence of 2329 bp shown in the sequence No. 2 from each sequence of the DNA fragment-B2 and DNA fragment-C2.

[0116] An open reading frame (ORF) in this 2329 bp was retrieved, to find that the two kinds of protein were coded. Each amino acid sequence of these proteins was retrieved by the BLAST search, and as a result, an ORF (hereinafter referred to as bpmA) encoding a protein consisting of 395 amino acids having high homology to cytochrome P450 existed in the base 420 to base 1604 of the sequence No. 2. The bpmA had the highest homology (homology: 67.4%) to the amino acid sequence of the psmA isolated from the A-1544 strain and also had a relatively high homology (homology: 64.8%) to cytochrome P450 soy (Soy C) of *Streptomyces griseus*. It was considered from this fact that the bpmA highly possibly encoded hydroxylating enzyme of the cytochrome P-450 type.

[0117] Also, an ORF (hereinafter referred to as bpmB) encoding a protein having a high homology to ferredoxin of a 3Fe-4S type that existed just downstream (the base 1643 to base 1834 of the sequence No. 2) of the bpmA. The protein encoded by the bpmB consisted of 64 amino acids, and had the highest homology (81.0%) to the amino acid sequence of the psmb isolated from the A-1544 strain and a relatively higher homology (homology: 76.2%) to the amino acid sequence assumed to be that of ferredoxin just downstream of the amino acid sequence assumed to be cytochrome P450 (CYP105D5) of *Streptomyces coelicolor* A3(2). Therefore, it was considered that the bpmB served to transfer electrons and participated in hydroxylation together with the bpmA.

Example 8 Production of a transformant having the bpmA and the bpmB

(1) Preparation of a DNA fragment containing both the bpmA and the bpmB derived from the Mer-11107 strain

[0118] A primer 07-NdeF (sequence No. 14) obtained by adding a NdeI site to the 5' terminal and a primer 07-SpeR (sequence No. 15) obtained by adding a SpeI site to the 5' terminal were designed and produced on reference to the nucleotide sequence of the sequence No. 2 analyzed in Example 7. Next, these two types of primers (07-NdeF and 07-SpeR) and the Mer-11107 strain chromosome DNA obtained in Example 7(1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a two-stage reaction including denaturing carried out at 98°C for 20 seconds and annealing and elongation carried out at 68°C for 2 minutes 30 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.).

[0119] As a result, a DNA fragment (hereinafter referred to as a DNA fragment-D2) having a size of about 1.5 kbp and containing the psmA and the psmb was amplified. The DNA fragment-D2 was recovered from the PCR amplified reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.).

(2) Architecture of a plasmid pTC-D07

[0120] pT7NS-CamAB (see WO03/087381) was digested by respective restriction enzymes NdeI and SpeI in a H

buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol and 100 mM NaCl) to obtain a plasmid digested products. Similarly, the DNA fragment-D2 obtained in the above (1) was digested by respective restriction enzymes NotI and SpeI. The obtained digested product of the DNA fragment-D2 and the plasmid digested product were bound using DNA Ligation Kit ver. 2 (TAKARA HOLDINGS INC.). Thereby, a plasmid (referred to as a plasmid pTC-D07) about 9.5 kbp in size which was an architecture of a combination of the DNA fragment-D2 containing both the bpmA and the bpmB therein and the plasmid pT7NS-CamAB was formed.

(3) Preparation of E. coli transforming strain BL21 (DE3)/pTC-D07

[0121] Using the plasmid pTC-D07 prepared in the above (2), a competent cell (Novagen) of *Colibacillus* BL21 (DE3) was transformed. Thereby, E. coli BL21 (DE3)/pTC-D07 strain transformed by the plasmid pTC-D07 was obtained.

Example 9: Conversion of the macrolide compound 11107B into the 11107D by the E. coli transformant having the bpmA and the bpmB

[0122] The transformed E. coli BL21(DE3)/pTC-D07 strain obtained in Example 8(3) and a frozen seed of a BL21 (DE3)/pT7NS-CamAB strain were inoculated into a 15 mL test tube containing 3 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing 50 µg/mL of ampicillin and shake-cultured at 37°C for 20 hours. 500 µL of the seed culture broth was inoculated into a 250 mL Erlenmeyer flask containing 50 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing 50 µg/mL of ampicillin and shake-cultured at 32°C for 4 hours. Then, 50 µL of 100 mM IPTG (isopropyl-β-D-thiogalactopyranoside) and 50 µL of 80 mg/mL 5-aminolevulinic acid were successively added and the medium was shake-cultured at 32°C for 5 hours. The obtained culture broth was centrifuged (5000 rpm, 10 minutes) to collect the mycelia. The mycelia were then suspended in 1.75 mL of a 100 mM phosphate buffer solution (pH 6.1), to which were then added 250 µL of 80% glycerol and 12.5 µL of 40 mg/mL macrolide compound 11107B. The conversion reaction solution obtained in this manner was reacted at 28°C for 24 hours. 400 µL of the reaction solution was extracted with 600 µL of methanol and the extract was subjected to HPLC to measure each amount of macrolide compounds 11107B and 11107D. The results are shown in Table 6.

[0123] Also, the details of the condition of HPLC are shown below.

Analyzer: Shimadzu HPLC 10Avp

Column: Develosil ODS UG-3 (φ4.6 mm × 250 mm 3 µm)

Mobile phase: 45% to 55% methanol (0 to 5 minutes)

55% methanol (5 to 13 minutes)

55% to 70% methanol (13 to 17 minutes)

70% methanol (17 to 21 minutes)

45% methanol (21 to 25 minutes)

Flow rate: 1.2 mL/min.

Detection: UV 240 nm

Injection capacity: 5 µL

Column temperature: 40°C

Analyzing time: 25 minutes

Retention time: 11107B 12.2 minutes

11107D 4.2 minutes

Table 6

mg/L	BL21 (DE3)/pT7NS-CamAB	BL21 (DE3)/pTC-D07
11107B	162	156
11107D	0.00	0.78

[0124] As a result, the peak of the macrolide compound 11107D was not observed in the case of the E. coli BL21 (DE3)/pT7NS-CamAB strain used as a control, whereas the peak of the macrolide compound 11107D was obtained in the case of the BL21 (DE3)/pTC-D07 strain containing the bpmA and bpmB. This fact suggests that the bpmA and the bpmB participate in the conversion of the macrolide compound 11107B into the macrolide compound 11107D. Example 10 Determination of the nucleotide sequence of a gene derived from the A-1560 strain (FERM BP-10102)

## (1) Preparation of a DNA of the A-1560 strain chromosome

[0125] The A-1560 strain was inoculated into a medium containing 1% of glucose, 0.4% of malt extract and 1% of yeast extract and cultured at 28°C for 3 days. The obtained culture broth was centrifuged at 3000 rpm for 10 minutes to collect the mycelia. A chromosome DNA was prepared using Blood & Cell Culture kit (QIAGEN Co.) from the mycelia.

(2) Cloning of a partial sequence of a DNA encoding a protein having the activity in hydroxylating the 16-position of the macrolide compound 11107

[0126] Mix primers (5Dm-3F (sequence no. 4) and 5Dm-2R (sequence No. 16) were designed and produced on reference to the amino acid sequence estimated as that of the cytochrome P450 (CYP105D5) of *Streptomyces coelicolor* A3(2).

[0127] In order to promote reactivity taking the fluctuation of a codon into account, mixed bases S (=C+G) and Y (=C+T) were used.

[0128] Next, these two types of primers (5Dm-3F and 5Dm-2R) and the A-1560 strain chromosome DNA obtained in the above (1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a three-stage reaction including denaturing carried out at 98°C for 20 seconds, annealing carried out at 50°C for 2 minutes and elongation carried out at 68°C for 30 seconds 35 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.). As a result, a DNA fragment (hereinafter referred to as a DNA fragment-A3) having a size of about 750 bp was amplified. It is highly possible that this DNA fragment-A3 is a part of the DNA encoding a protein having hydroxylating activity. The DNA fragment-A3 amplified by a PCR reaction was recovered from the reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.).

[0129] In order to obtain the DNA fragment-A3 in an amount enough to analyze the nucleotide sequence of the obtained DNA fragment-A3, the DNA fragment-A3 was bound with a plasmid vector pT7Blue T (Novagen Co.) by using DNA Ligation Kit ver.2 (TAKARA HOLDINGS INC.) to transform *E. coli* JM109 strain (Stratagene Co.). Thereafter, the transformed *E. coli* was selected using a L-broth agar media (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl, 1.5% agar) containing ampicillin (50 µg/mL), X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside; 40 µg/mL) and IPTG (isopropyl-β-D-thiogalactopyranoside; 100 µM). The colony of the transformed *E. coli* thus isolated was cultured in a L-broth liquid medium (1% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing ampicillin (50 µg/mL). A plasmid DNA was separated from the mycelia of the proliferated transformed *E. coli* and purified by using a plasmid purifying kit (QIA filter Plasmid Midi Kit, QIAGEN Co.), to obtain enough amount of the DNA fragment-A3.

## (3) Analysis of the nucleotide sequence of the cloned DNA fragment-A3

[0130] The nucleotide sequence of the DNA fragment-A3 obtained in the above (2) was analyzed using a DNA nucleotide sequence analyzer (PE Biosystems 377XL) according to a dye terminator cycle sequence method. As the result of the nucleotide sequence analysis, it was clarified that the DNA fragment-A3 amplified by a PCR reaction had an exact size of 741 bp though it had been found to have a size of about 750 bp by the above measurement using electrophoresis (see the nucleotide sequence 618 to nucleotide sequence 1356 of the sequence No. 3). Since DNA sequences corresponding to the two types of primers used in the above PCR reaction were found at both ends of the above cloned 741 bp DNA sequence, it was clarified that the DNA fragment-A3 was singularly amplified by these two types of primers (5Dm-3F and 5Dm-2R) in the above PCR reaction.

## (4) Analysis of the neighboring region of the DNA fragment-A3

[0131] As mentioned above, the partial sequence of the DNA encoding a protein having hydroxylating activity derived from the A-1560 strain was determined. Therefore, the amplification, cloning and sequence analysis of the nucleotide sequence in the neighboring region extending from the upstream side to downstream side of the cloned fragment were accomplished by an inverse PCR method (Cell Technology vol. 14, p.591-593, 1995).

Specifically, the A-1560 strain chromosome DNA (see the above (1)) was digested by a restriction enzyme BamHI in a K buffer solution (50 mM Tris-HCl, pH 8.5, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol and 100 mM KCl), by a restriction enzyme KpnI in a L buffer solution (10 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub> and 1 mM dithiothreitol) and by a restriction enzyme SalI in a H buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol and 100 mM NaCl) respectively. The obtained each DNA fragment cut by the restriction enzymes was self-circularized using DNA Ligation Kit ver.2 (TAKARA HOLDINGS INC.).

[0132] On the other hand, primers (5PIN-2F (sequence No. 17) and 6PIN-2R (sequence No. 7)) were designed and produced based on the nucleotide sequence of the DNA fragment-A3.

[0133] Next, these two primers (5PIN-2F and 6PIN-2R) and the above self-circularized A-1560 strain chromosome



DNA as a template, were used to run a PCR reaction. In the PCR reaction, the cycle of a two-stage reaction involving denaturing carried out at 98°C for 20 seconds and annealing and elongation carried out at 68°C for 5 minutes was repeated 35 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and PCR amplifier (T Gradient, Biometra Co.).

[0134] As a result, a DNA fragment (DNA fragment-B3) about 4.5 kbp in size, a DNA fragment (DNA fragment-C3) about 3.0 kbp in size and a DNA fragment (DNA fragment-D3) about 1.7 kbp in size were amplified. It was highly possible that these DNA fragments were a DNA encoding a protein having hydroxylating activity and a DNA having a DNA sequence including those in the upstream and downstream regions of the former DNA.

[0135] The DNA fragment-B3, the DNA fragment-C3 and the DNA fragment-D3 were recovered from the PCR amplified reaction solution by SUPREC PCR (TAKARA HOLDINGS INC.). Next, as to the obtained DNA fragment-B3, DNA fragment-C3 and DNA fragment-D3, in order to obtain each DNA fragment in an amount enough to analyze the nucleotide sequence of the obtained DNA fragment, a plasmid vector pT7Blue T (Novagen Co.), DNA Ligation kit ver.2 (TAKARA HOLDINGS INC.), E. coli JM109 strain and a plasmid purifying kit (QIA filter Plasmid Midi Kit, QIAGEN Co.) were used in the same manner as the above (2), to obtain enough amount of each DNA fragment.

(5) Analysis of each nucleotide sequence of the DNA fragment-B3 (about 4.5 kbp in size), the DNA fragment-C3 (about 3.0 kbp in size) and the DNA fragment-D3 (about 1.7 kbp in size)

[0136] Each nucleotide sequence of the DNA fragment-B3, DNA fragment-C3 and DNA fragment-D3 obtained in the above (4) was analyzed using a DNA nucleotide sequence analyzer (PE Biosystems 377XL) according to a dye terminator cycle sequence method. The nucleotide sequence was thus analyzed to obtain the information of the nucleotide sequence of 1860 bp shown in the sequence No. 3 from each sequence of the DNA fragment-B3, DNA fragment-C3 and DNA fragment-D3.

[0137] An open reading frame (ORF) in this 1860 bp was retrieved, to find that the two kinds of protein were encoded. Each amino acid sequence of these proteins was retrieved by the BLAST search, and as a result, an ORF (hereinafter referred to as tpmA) encoding a protein consisting of 404 amino acids having high homology to cytochrome P450 existed in the base 172 to base 1383 of the sequence No. 3. The tpmA had the highest homology (homology: 77.4%) to the amino acid sequence assumed to be that of cytochrome P450 (CYP105D5) of *Streptomyces coelicolor* A3 (2) and also a high homology (homology: 76.6%) to the amino acid sequence of the tpmA isolated from the A-1544 strain. It was considered from this fact that the tpmA was highly possibly a gene encoding hydroxylating enzyme of the cytochrome P-450 type.

[0138] Also, an ORF (hereinafter referred to as tpmB) encoding a protein having a high homology to ferredoxin of a 3Fe-4S type existed just downstream (the base 1399 to base 1593 of the sequence No. 3) of the tpmA. The protein encoded by the tpmB consisted of 66 amino acids, and had the highest homology (81.0%) to the amino acid sequence of the tpmB isolated from the A-1544 strain and also a high homology (homology: 82.5%) to the amino acid sequence assumed to be that of ferredoxin just downstream of the amino acid sequence assumed to be cytochrome P450 (CYP105D5) of *Streptomyces coelicolor* A3 (2). Therefore, it was considered that the tpmB served to transfer electrons and coded ferredoxin participating in hydroxylation together with the tpmA.

Example 11 Production of a transformant having the tpmA and the tpmB

(1) Preparation of a DNA fragment containing both the tpmA and the tpmB derived from the A-1560 strain

[0139] A primer tpm-NdeF (sequence No. 18) obtained by adding a NdeI site to the 5' terminal and a primer tpm-SpeR (sequence No. 19) obtained by adding a SpeI site to the 5' terminal were designed and produced on reference to the nucleotide sequence of the sequence No. 3 analyzed in Example 10. Next, these two types of primers (tpm-NdeF and tpm-SpeR) and the A-1560 strain chromosome DNA obtained in Example 10(1) as a template, were used to run a PCR reaction. The PCR reaction was accomplished by repeating a two-stage reaction including denaturing carried at 98°C for 20 seconds and annealing and elongation carried out at 68°C for 2 minutes 30 times by using Takara LA Taq (TAKARA HOLDINGS INC.) and a PCR amplifier (T Gradient, Biometra Co.).

[0140] As a result, a DNA fragment (hereinafter referred to as a DNA fragment-E3) having a size of about 1.5 kbp and containing the tpmA and the tpmB was amplified. The DNA fragment-E3 was recovered from this PCR amplified reaction solution by SJPREC PCR (TAKARA HOLDINGS INC.).

(2) Architecture of a plasmid pTC-tpmAB

[0141] pTNS-CamAB (see WO03/087381) was digested by respective restriction enzymes NdeI and SpeI in a H buffer solution (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol and 100 mM NaCl) to obtain plasmid digested products. Similarly, the DNA fragment-E3 obtained in the above (1) was digested by respective restriction enzymes NdeI

and *SpeI*. The obtained digested product of the DNA fragment-E3 and the plasmid digested product were bound using DNA Ligation Kit ver. 2 (TAKARA HOLDINGS INC.). Thereby, a plasmid (referred to as a plasmid pTC-tpmAB) about 9.5 kbp in size which was an architecture of a combination of the DNA fragment-E3 containing both the tpmA and the tpmB therein and the plasmid pT7NS-CamAB was formed.

### (3) Preparation of *E. coli* transforming strain BL21 (DE3)/pTC-tpmAB

**[0142]** Using the plasmid pTC-tpmAB prepared in Example 11(2), a competent cell (Novagen) of *Colibacillus* BL21 (DE3) was transformed, to give *E. coli* BL21 (DE3)/pTC-tpmAB strain transformed by the plasmid pTC-tpmAB.

Example 12: Conversion of the 11107B into the 11107D by the *E. coli* transformant having the tpmA and the tpmB

**[0143]** The transformed *E. coli* BL21(DE3)/pTC-tpmAB strain obtained in the above (3) and a frozen seed of a BL21 (DE3)/pT7NS-CamAB strain were inoculated into a 15 mL test tube containing 3 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing 50 µg/mL of ampicillin and shake-cultured at 37°C for 20 hours. 500 µL of the seed culture broth was inoculated into a 250 mL Erlenmeyer flask containing 50 mL of a L-broth medium (1.0% bactotripton, 0.5% yeast extract, 0.5% NaCl) containing 50 µg/mL of ampicillin and shake-cultured at 32°C for 4 hours. Then, 50 µL of 100 mM IPTG (isopropyl-β-D-thiogalactopyranoside) and 50 µL of 80 mg/mL 5-aminolevulinic acid were successively added thereto, and the medium was shake-cultured at 32°C for 5 hours. The obtained culture broth was centrifuged (5000 rpm, 10 minutes) to collect the mycelia. The mycelia were suspended in 1.75 mL of a 100 mM phosphate buffer solution (pH 6.1), and 250 µL of 80% glycerol and 12.5 µL of 40 mg/mL macrolide compound 11107B were added thereto. The conversion reaction solution obtained in this manner was reacted at 28°C for 24 hours. 400 µL of the reaction solution was extracted with 600 µL of methanol and the extract was subjected to HPLC to measure each amount of macrolide compounds 11107B and 11107D. The results are shown in Table 7. Also, the details of the condition of HPLC are shown below. Analyzer: Shimadzu HPLC 10Avp  
Column: Develosil ODS UG-3 (φ4.6 mm × 250 mm 3 µm)  
Mobile phase: 45% to 55% methanol (0 to 5 minutes)  
55% methanol (5 to 13 minutes)  
55% to 70% methanol (13 to 17 minutes)  
70% methanol (17 to 21 minutes)  
45% methanol (21 to 25 minutes)  
Flow rate: 1.2 mL/min.  
Detection: UV 240 nm  
Injection capacity: 5 µL  
Column temperature: 40°C  
Analyzing time: 25 minutes  
Retention time: 11107B 12.2 minutes  
11107D 4.2 minutes


Table 7

mg/L	BL21(DE3)/pT7NS-CamAB	BL21(DE3)/pTC-tpmAB
11107B	141	128
11107D	0	16

**[0144]** As a result, the peak of the macrolide compound 11107D was not observed in the case of the *E. coli* BL21 (DE3)/pT7NS-CamAB strain used as a control, whereas the peak of 11107D was obtained in the case of the BL21(DE3)/pTC-tpmAB strain containing the tpmA and tpmB. This fact suggests that the tpmA and the tpmB participate in the conversion of 11107B into 11107D.

Example 13: Conversion of 11107H into 11107CB represented by the following formulae by a self-cloning strain

**[0145]**



## (1) Preparation of a transformant reaction solution

[0146] A medium containing 2.0% of Stabilose, 2.0% of glucose, 2.0% of a soybean meal (Honen Soypro), 0.5% of yeast extract and 0.32% of  $\text{CaCO}_3$  and having a pH of 7.4 was prepared. A 250 mL Erlenmeyer flask was charged with 25 mL of the medium, which was then sterilized under heating at 121°C for 20 minutes and thiostrepton was added to the medium such that its final concentration was 25 mg/L. Then, 1% of an A-1544/pJDMG strain from frozen seed was inoculated to culture the seed at 28°C and 220 rpm for 3 days. 1% of the seed culture broth was added in a medium having the same composition to carry out main culturing at 28°C and 220 rpm for 2 days. After the main culturing was finished, mycelia were collected from the culture broth by centrifugation and suspended in 20 mL of phosphate buffer solution having a pH of 6.5. The substrate 11107H (100 g/L DMSO solution) was added in this mycelia suspended solution such that its final concentration was 2000 mg/L to run a conversion reaction at 28°C and 220 rpm for 16 hours.


## (2) Isolation of amacrolide compound 11107CB from a transformant reaction solution

[0147] Mycelia were isolated from a conversion reaction solution (in an amount corresponding to 6 flasks) obtained from the same operation, by centrifugation and the centrifuged supernatant was extracted with the equal amount of ethyl acetate twice. The extract was concentrated and then the residue was purified by thin layer chromatography (MERCK Silicagel 60 F254' 0.5 mm, developing solution: toluene:acetone=1:1), to obtain 119.5 mg of 11107CB.

<sup>1</sup>H-NMR spectrum ( $\text{CD}_3\text{OD}$ , 500MHz):  $\delta$  ppm (integral, multiplicity, coupling constant J(Hz)): 0.81(3H,d,J=6.7Hz), 0.89(3H,d,J=7.0), 0.94(3H,t,J=7.4Hz), 1.25(3H,s), 1.30-1.20(1H,m), 1.33(3H,s), 1.55-1.40(2H,m), 1.65(1H,dd,J=6.3,14.0Hz), 1.75(3H,s), 1.88(1H,dd,J=5.4,14.0Hz), 2.07(3H,s), 2.68-2.40(4H,m), 2.89(1H,m), 3.51(1H,m), 4.51(1H,m), 4.97(1H,d,J=8.6Hz), 4.99(1H,d,J=9.3Hz), 5.30(1H,dd,J=9.7,15.2Hz), 5.52(1H,dd,J=9.4,15.2Hz), 5.58(1H,dd,J=1.9,15.5Hz), 5.78(1H,dd,J=2.8,15.5Hz), 5.85(1H,d,J=15.3Hz), 6.07(1H,d,J=11.0Hz), 6.51(1H,dd,J=11.0,15.3Hz)

Example 14: Conversion of 11107L into 11107CG represented by the following formulae respectively by a self-cloning strain

[0148]



## (1) Preparation of a transformant reaction solution

[0149] A medium containing 2.0% of stabilose, 2.0% of glucose, 2.0% of a soybean meal (Honen Soypro), 0.5% of yeast extract and 0.32% of  $\text{CaCO}_3$  and having a pH of 7.4 was prepared. A 250 mL Erlenmeyer flask was charged with 25 mL of the medium, which was then sterilized under heating at 121°C for 20 minutes and thiostrepton was added to the medium such that its final concentration was 25 mg/L. Then, 1% of an A-1544/pLIDMG strain from frozen stock was inoculated to cultivate the seed culture at 28°C and 220 rpm for 3 days. 1% of this seed culture broth was added in a medium having the same composition to carry out main cultivation at 28°C and 220 rpm for 2 days. After the main cultivation was finished, mycelia were collected from the culture broth by centrifugation and suspended in 20 mL of phosphate buffer solution having a pH of 8.5. The substrate 11107L (100 g/L DMSO solution) was added to this mycelia suspension solution such that its final concentration was 1600 mg/L to run a conversion reaction at 28°C and 220 rpm for 16 hours.

## (2) Isolation of a macrolide compound 11107CG from a transformant reaction solution

[0150] Mycelia were isolated from the conversion reaction solution by centrifugation and the centrifuged supernatant was extracted with the equivalent amount of ethyl acetate twice. The extract layers were concentrated and then the residue was purified by thin layer chromatography (MERCK Silicagel 60 F254 0.25 mm, developing solution: toluene: acetone=1:1), to obtain 25 mg of 11107CG.

ESI-MS  $m/z$  633 ( $M+\text{Na}^+$ )

$^1\text{H-NMR}$  spectrum ( $\text{CD}_3\text{OD}$ , 500MHz):  $\delta$  ppm (integral, multiplicity, coupling constant J (Hz)):

0.88(3H, d,  $J=6.7\text{Hz}$ ), 0.90(3H, d,  $J=7.0\text{Hz}$ ), 0.94(3H, d,  $J=7.4\text{Hz}$ ), 1.18(3H, s), 1.30-1.20(1H, m), 1.39(3H, s), 1.56-1.40(2H, m), 1.66(1H, dd,  $J=6.2, 14.0\text{Hz}$ ), 1.79-1.69(2H, m), 1.81(3H, d,  $J=1.0\text{Hz}$ ), 1.86(1H, dd,  $J=5.4, 14.0\text{Hz}$ ), 2.05(3H, s), 2.52(1H, dd,  $J=4.2, 15.2\text{Hz}$ ), 2.64-2.55(1H, m), 2.67(1H, dd,  $J=2.2, 7.9\text{Hz}$ ), 2.78(1H, dd,  $J=3.0, 15.2\text{Hz}$ ), 2.90(1H, d,  $J=2.2, 5.6\text{Hz}$ ), 3.52(1H, dt,  $J=4.4, 8.8\text{Hz}$ ), 3.75(1H, m), 4.98(1H, dd,  $J=2.8, 11.3\text{Hz}$ ), 5.08(1H, d,  $J=9.7\text{Hz}$ ), 5.13(1H, d,  $J=9.6\text{Hz}$ ), 5.61(1H, dd,  $J=9.9, 15.2\text{Hz}$ ), 5.75(1H, dd,  $J=9.7, 15.2\text{Hz}$ ), 5.88(1H, d,  $J=15.3\text{Hz}$ ), 6.13(1H, d,  $J=11.0\text{Hz}$ ), 6.54(1H, dd,  $J=11.0, 15.3\text{Hz}$ )

## Industrial applicability

[0151] A 12-membered macrolide compound which has hydroxyl group at the 16-position and is excellent in antitumor

activity and stability in an aqueous solution can be produced efficiently by using a transformant obtained by transformation using a plasmid carrying the DNA of the present invention.

5

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

<110> Mercian Corporation  
 <110> Eisai Co., Ltd  
 <120> DNA related to hydroxylation of macrolide compounds  
 <130> D4063PCT  
 <150> JP 2003-396828  
 <151> 2003-11-27  
 <160> 19  
 <210> 1  
 <211> 3793  
 <212> DNA  
 <213> Streptomyces sp.  
 <220>  
 <221> CDS  
 <222> (1322).. (2548)  
 <220>  
 <221> CDS  
 <222> (2564).. (2761)  
 <400> 1  
 ctgcagctcg acgtccgggt cggacttcac gttagagtag cagaccggat gcctggccgc 60  
 acccccagc gaggcagccg cccgctaact cccctcrtcc tcgaccgcga tcagccgcgt 120  
 ctccgcatc ttccgctcc gcgcgccccg ggtggtgagc acgataccg gcagcccggt 180  
 gtcccgagc gtggtgacct tgggtccccc ggaactctcg tacgctcga cctgctccgc 240  
 caccactgc gtccgctgg gctcgtactc ggcctcaagl ggcagggat cgtctctt 300  
 cgtcggctcg ccgagtggtg ctccggacgg tcccaactcc cgcggcgcc cgaatcacc 360  
 gtaccgcatg ccccttcgcc cgaacgggtg atcacccttc cggccatccg gtctccgca 420  
 cccgagcagc cagatcagc gcctgggaga ccaagccgtt gaccagccgc ccccggtgg 480  
 cgtcagggc ggcagcagc agcagccccc ccccgccag cagtagctgc cagctccgcg 540  
 acgcgagaa ggcgcgcgc gcgaacacgc ccglttcag gcccctgctc ggcagccgag 600  
 cgcgcctgcc ggcaccagc ggcagcaagt agaccacgt catggatgg agcagcgtag 660  
 tcccgagag ggcagagtaa gcccctgcc cccctggaac cgccttcc ggcgcgggtg 720  
 tgagccgatg ggcagcatg tcccgtaggg cagcagcgc ccccgccagc ggcagccgcg 780  
 cgaagaccag ccccgagccc cagcgcagcg gcttcagcac cgcggcgagc tgctccgca 840  
 ggcgcgcgcc gccacgctc gcagcagcgc cgtacagccc gtccggcggt gcgacgccga 900  
 gcctcccgca ggcgcggatg cgcagcaggg tccggcggtt gaggggagcc agatagctcc 960  
 cgcctccgct cagcgccatc gcagtcaggt acccgccgag cagcccgccg agcagccgct 1020  
 cgtcagcgcc cctgcgggac ggtttctccc ggggacggcg ggcctgctgt ccccccggca 1080  
 cgcgcggggc gctgcggcgc gctctcgca ggaaggagcc tgtagggagc atggccgat 1140  
 ctggggccgc cgcgcggccc accgcaaat gaattacgc gcttccagc ccccgccgag 1200  
 ctgcctcttc ggcacttca cccgtacgc cgaactggcc gaacttcgtg tcgcccata 1260  
 ggtgcttcgg gcatctaag agaatcgca cagcgacct ctgctcgc gaggctcttc 1320  
 c atg acc gaa ctg acc gac atc acc ggc cgc ggg acc cgc gcc gaa 1366  
 Met Thr Gly Leu Thr Asp Ile Thr Gly Pro Gly Thr Pro Ala Glu  
 1 5 10 15  
 ccc gtc gca ttc ccc cag gac cgc acc tgc ccc tac cac ccc ccc acc 1414  
 Pro Val Ala Phe Pro Gln Asp Arg Thr Cys Pro Thr His Pro Pro Thr  
 20 25 30  
 gga tac ggc cgc cta cgc gac ggg cgc atg tcc cgc gtc acc ctc 1462  
 Gly Tyr Gly Pro Leu Arg Asp Gly Arg Ser Leu Ser Arg Val Thr Leu  
 35 40 45  
 ttc gac ggc cgc gag gtc tgg atg gtc acc ggc cac gcc acc gcc cgc 1510  
 Phe Asp Gly Arg Glu Val Trp Met Val Thr Gly His Ala Thr Ala Arg

	50	55	60	
5	ccg ctg ctc ccg gac ccc ccg	ctg tcc acc gac ccg acc ctc ccg ggc		1558
	Ala Leu Leu Ala Asp Pro Arg	Leu Ser Thr Asp Arg Thr Leu Pro Gly		
	65	70	75	
	ttc ccc gtc ccc acc gcc cgc	ttc ccg gcc gtc cgc gac ccg ccg gtc		1606
	Phe Val Pro Thr Ala Arg Phe	Ala Ala Val Arg Asp Arg Arg Val		
	80	85	90	95
10	ccg ctg ctc ggc gtc gac gac	ccg gtc cac cag acc cag ccg ccg gtc		1654
	Ala Leu Leu Gly Val Asp Asp	Pro Val His Gln Thr Gln Arg Arg Met		
	100	105	110	
	atg atc ccg tgc ttc acc ctc	aag cgc ccg gcc ggc ctc ccg ccg acc		1702
	Met Ile Pro Ser Phe Thr Leu	Lys Arg Ala Ala Gly Leu Arg Pro Thr		
	115	120	125	
15	atc cag ccg acc gtc gac ggc	ctg ctg gac ccg atg atc gac aag ggc		1750
	Ile Gln Arg Thr Val Asp Gly	Leu Leu Asp Ala Met Ile Glu Lys Gly		
	130	135	140	
	ccg ccg gcc gac gtc gtc tcc	gcc ttc gcc ctg ccc gtc ccc tgc gtc		1798
	Pro Pro Ala Glu Leu Val Ser	Ala Phe Ala Leu Pro Val Pro Ser Val		
	145	150	155	
20	gtc atc tgc ggc ctg ctc ggc	gtc ccg tac gcc cac cag ttc ttc		1846
	Val Ile Cys Gly Leu Leu Gly	Val Pro Tyr Ala Asp His Glu Phe Phe		
	160	165	170	175
	gag gaa cag tcc cgc ccg ctg	ctg cgc ggt ccc acc gcc acc tgc		1894
	Glu Glu Gln Ser Arg Thr Leu	Leu Arg Gly Pro Thr Ala Ala Asp Ser		
	180	185	190	
25	caa ggc ccg cgc gac ccg ctc	gag gag tac ctc gcc ggc ctg atc gac		1942
	Gln Gly Ala Arg Glu Arg Leu	Glu Glu Tyr Leu Gly Gly Leu Ile Asp		
	195	200	205	
	gac aag gag ccg ccg gcc gaa	ccc gcc gac gtc ctg gac gac ctc		1990
	Asp Lys Glu Arg Gln Ala Glu	Pro Gly Asp Gly Val Leu Asp Asp Leu		
	210	215	220	
30	gtc cac cag ccg ctg cgc acc	gcc gag ctg gac ccg cgc gac gtc gtc		2038
	Val His Gln Arg Leu Arg Thr	Gly Glu Leu Asp Arg Arg Asp Val Val		
	225	230	235	
	gcc ctg gcc gtc atc ctg ctc	gtc gcc gcc cag acc gcc aac		2086
	Ala Leu Ala Val Ile Leu Leu	Val Ala Gly His Glu Thr Thr Ala Asn		
	240	245	250	255
35	atg atc tcc ctc ggc acc tac	acc ctg ctg cgc gcc ccc gcc ccg ctg		2134
	Met Ile Ser Leu Gly Thr Tyr	Thr Leu Leu Arg His Pro Gly Arg Leu		
	260	265	270	
	gcc gag ctg cgc gcc gac ccg	gcc ctg ctg ccc gcc gcc gtc ggc ggc		2182
	Ala Glu Leu Arg Ala Asp Pro	Ala Leu Leu Pro Ala Ala Val Glu Glu		
	275	280	285	
40	ctg atg ccg atg ctc tgc atc	gcc gac ggc ctg ctg cgc ctc gcc ctg		2230
	Leu Met Arg Met Leu Ser Ile	Ala Asp Gly Leu Leu Arg Leu Ala Leu		
	290	295	300	
	gag gac atc gag atc gcc gcc	gcc acc atc ccg gcc gcc gag gcc gtc		2278
	Glu Asp Ile Glu Ile Ala Gly	Ala Thr Ile Arg Ala Gly Glu Gly Val		
	305	310	315	
45	ctg ttc tcc acc tgc ctg atc	aac cgc gac gag tcc gtc ttc gac gac		2326
	Leu Phe Ser Thr Ser Leu Ile	Asn Arg Asp Glu Ser Val Phe Asp Asp		
	320	325	330	335
	ccc gac acc ctg gac ttc cac	ctc tcc acc cgc cac cac gtc gcc ttc		2374
	Pro Asp Thr Leu Asp Phe His	Arg Ser Thr Arg His His Val Ala Phe		
	340	345	350	
50	ggt ttc gcc atc cac cag tgc	ctg gcc ccg aac ctg gcc cgc gcc gag		2422
	Gly Phe Gly Ile His Gln Cys	Leu Gly Gln Asn Leu Ala Arg Ala Glu		
	355	360	365	
	ctg gag atc gcc ctg gcc acc	ctg ctg gag ccg ctc ccc gcc ctc ccg		2470
	Leu Glu Ile Ala Leu Gly Thr	Leu Leu Glu Arg Leu Pro Gly Leu Arg		
	370	375	380	

	ctg gcc gcg ccc gcc gag gag atc ccg ttc aaa ccc ggc gac acg atc	2518
	Leu Ala Ala Pro Ala Glu Glu Ile Pro Phe Lys Pro Gly Asp Thr Ile	
5	385 390 395	
	cag ggg atg ctg gaa ctc ccc gtg acc tgg taa gaggctctgg tc atg cac	2569
	Gln Gly Met Leu Glu Leu Pro Val Thr Trp Met His	
	400 405 410	
	atc gac atc xac aag gac cgc tgc atc ggc gcc cag tgc ggc ctg	2617
	Ile Asp Ile Asp Lys Asp Arg Cys Ile Gly Ala Gly Gln Cys Ala Leu	
10	415 420 425	
	gcc gcc ccg ggc gtg ttc acc cag gac gac ggc lac ggc acc ctg	2665
	Ala Ala Pro Gly Val Phe Thr Gln Asp Asp Gly Tyr Ser Thr Leu	
	430 435 440	
	ctc ccc ggc cgc gag gac ggc ggc ggc cgc atg gtc cgg gag gcc	2713
	Leu Pro Gly Arg Glu Asp Gly Gly Gly Asp Pro Met Val Arg Glu Ala	
15	445 450 455	
	gcc cgc gcc tgc ccg gtg agc gcc atc cgg gta acc gaa ccg gcc gcc	2761
	Ala Arg Ala Cys Pro Val Ser Ala Ile Arg Val Thr Glu Pro Ala Gly	
	460 465 470 475	
20	tga ggcggggccc ggcggccgcg gccggtgcc gggaccgcgc ttccagttc agtagg	2820
	gltgtgcat gaccctcag gccgggaagc ccttcctta cgtctgttc tgcggggc	2880
	ggggccccc cggagtcacc agctgtaic ggcgcggcca ggcggggc tgggggttg	2940
	gggtcclggc cagctccgtg gcaalgggc ggtcttcca cagcttgcg gtccgggttg	3000
25	tggggggc cccatctgc tggcttggc gcttccgac caatccggc cgtttccgc	3060
	ggcggggc gttgtgtg gtcgggca cctcaaac cgtcaaacg tggggggc	3120
	gttcggca cgcctggc gtgggagc tctggggc ggcgggct ggcgtggca	3180
	tccggctct ggcctgggtt ggggagcgc tggcgccca ccccgtaac cggggggc	3240
	ttctcgtct gcttgggtt gctcttcgt tggcgagcc gtacgggac cggggggc	3300
	aggagggca ggcggaggtt gacggggc ggttgcctt ggaagacc cggggggc	3360
30	tggagggc ctgaacccc tcccgagcc gtggggctt tctgacgt tggagggc	3420
	cctaacggca ggtcagccc gggcgggcca gcatgcccc ggtgtgagg tctggggc	3480
	ggggagcca gtggccagc ctggagacca cgtgggagca gtacggccc aggttgccc	3540
	ggacttacc cgttcggga cggcgggct gacggcggt cagcgcgac tccaggggt	3600
	acggagggc ggttttgg gtacggggc accaggggt tggcgagc ggcctcttc	3660
	gtggggttc gaccccggt gggcgggc cgttgagtc cagggggc gcttccctg	3720
35	ccctctgac tctccggc gaccgttag gtacgttg tgggtgctt ggcggcag	3780
	gttcgggtt gac	3793

<210> 2  
 <211> 2329  
 <212> DNA  
 <213> Streptomyces sp.

<220>  
 <221> CDS  
 <222> (420).. (1604)

<220>  
 <221> CDS  
 <222> (1643).. (1834)

<400> 2  
 ggtaccgag gtggcgccg cgttcggcg ggtaccgac cggcgtatc gctatgtgc 60  
 cgcctcttc ggcggcggtt gcttcccca gggcgagcc cgggaccgc gcttcttgc 120  
 gtacacggc tacttggc acaccagct cggatggc gttcgaga gcttccggc 180  
 cggggggc cagcagcgt atctggatg cgtatggac accctgtat ggcggggc 240  
 cggggggc gaggcgac atgtcaca ctgagagg ttggcgagc tggcgcgag 300  
 acatggggc tatcgggc atgaggtg atcgcgccg cgaagacgg tggcgcgag 360



	cgctggccalc	tcacacaga	gcaacicgag	ccacttgaga	cicglacggg	aggazatic	419
5	gtg acc gaa gcc atc ccc tac tti	cag aac cgc acc tgt ccc tac cac	467				
	Val Thr Glu Ala Ile	Pro Tyr Phe Gln Asn Arg Thr Cys Pro Tyr His					
	1	5	10	15			
	ccg ccc gcc gcc tat cag cca ctg cgc ggg gcc ggc cgc cta asc cat	515					
	Pro Pro Ala Ala Tyr Gln Pro Leu Arg Gly Ala Gly Pro Leu Ser His						
10	20	25	30				
	gtc acg ttc tac gac ggc cgc aag gte lgg cgc gtc acc ggc cac ccc	563					
	Val Thr Phe Tyr Asp Gly Arg Lys Val Trp Ala Val Thr Gly His Pro						
	35	40	45				
	gag gca cgg cgc ctg ctg acc gac cag cga ctc tcc gcc gac cgg cag	611					
	Glu Ala Arg Ala Leu Leu Thr Asp Gln Arg Leu Ser Ala Asp Arg Gln						
15	50	55	60				
	aac cgg gcc ttc cgc gtc ccc ttc gaa cgc ttc cgc gcc atc cgc cgc	659					
	Asn Pro Ala Phe Pro Val Pro Phe Glu Arg Phe Ala Ala Ile Arg Arg						
	65	70	75	80			
	gtc cgc acg cgc ctg atc ggc gtc gac gac cgc gag cac aac acc cag	707					
	Val Arg Thr Pro Leu Ile Gly Val Asp Asp Pro Glu His Asn Thr Gln						
20	85	90	95				
	cgc cgc atg cta atc ccc agc ttc agc ctc aag cgc acc gcc gca ctg	755					
	Arg Arg Met Leu Ile Pro Ser Phe Ser Leu Lys Arg Thr Ala Ala Leu						
	100	105	110				
	cgc cgc gag atc cag cgc atc gtc gac ggc ctg ctg gac cgc atg ctg	803					
	Arg Pro Glu Ile Gln Arg Ile Val Asp Gly Leu Leu Asp Arg Met Leu						
25	115	120	125				
	gat cag ggc cgc ccc acc gac ctg gtc tcc cgc ttc gcc ctg cgc gtc	851					
	Asp Gln Gly Pro Pro Thr Glu Leu Val Ser Ala Phe Ala Leu Pro Val						
	130	135	140				
	ccg tgc atg gtc atc tgc gca ctg ctg gga gtc tca tac gcc gac cat	899					
	Pro Ser Met Val Ile Cys Ala Leu Leu Gly Val Ser Tyr Ala Asp His						
30	145	150	155	160			
	gag ttc ttc gag gag gag tcc cgc cgc atc ctg cgc ggc cgc tgc gcc	947					
	Glu Phe Phe Glu Glu Glu Ser Arg Arg Ile Leu Arg Gly Arg Ser Ala						
	165	170	175				
	gag gag ggc gag gac gcc cgc ctg aag ctg gag gag tac ttc acc ggc	995					
	Glu Glu Ala Glu Asp Ala Arg Leu Lys Leu Glu Tyr Phe Thr Gly						
35	180	185	190				
	ctg atc gcc gcc gag gag aag aac cgc gcc gac ggc ctg ctg gac gag	1043					
	Leu Ile Ala Ala Lys Glu Lys Asn Pro Gly Asp Gly Leu Leu Asp Glu						
	195	200	205				
	ctg atc gag gac cgc ctg cgc acc ggc cgc ctg acc cgc gac gag ctg	1091					
	Leu Ile Glu Asp Arg Leu Arg Thr Gly Ala Leu Thr Arg Asp Glu Leu						
40	210	215	220				
	gtc cgc ctg gcc atg atc ctg ctg gtc gcc gcc cat gag acc acc gcc	1139					
	Val Arg Leu Ala Met Ile Leu Leu Val Ala Gly His Glu Thr Thr Ala						
	225	230	235	240			
	aac atg atc tgc ctg gcc acc ttc acc ctg ctg gac cac ccc gag cag	1187					
	Asn Met Ile Ser Leu Gly Thr Phe Thr Leu Leu Asp His Pro Glu Gln						
45	245	250	255				
	ctg ggc cag ctg aag gcc gac gag gcc ctg atg cgc gcc gcc atc gag	1235					
	Leu Ala Glu Leu Lys Ala Asp Glu Gly Leu Met Pro Ala Ala Ile Glu						
	260	265	270				
	gag ctg ctg cga ttc ctg tcc atc cgc gac gcc ctg ctg cgc gtc cgc	1283					
	Glu Leu Leu Arg Phe Leu Ser Ile Ala Asp Gly Leu Leu Arg Val Ala						
50	275	280	285				
	acg gag gac atc gag atc gcc ggt cag gtc atc cgc gcc gac gac cgc	1331					
	Thr Glu Asp Ile Glu Ile Gly Gly Gln Val Ile Arg Ala Asp Asp Ala						
	290	295	300				
	gtc ctg ttc ccc gcc tca ctg atc aac cgc gac gag gcc gcc tat cgc	1379					
55	Val Leu Phe Pro Ala Ser Leu Ile Asn Arg Asp Glu Ala Ala Tyr Pro						

	305	310	315	320	
5	gca ccc gac gag cta gac ctc ggc cgt tca gcc cgc cat cac gta cgc				1427
	Ala Pro Asp Glu Leu Asp Leu Gly Arg Ser Ala Arg His His Val Ala				
	325	330	335		
	tcc gcc ttc ggc atc cac cag tgc cta ggc cag aac ctc gcc cgc cgc				1475
	Ser Gly Phe Gly Ile His Gln Cys Leu Gly Gln Asn Leu Ala Arg Ala				
10	340	345	350		
	gag atg gag atc gcc cta gac tca cta ttc acc agg atc cgc cag cta				1523
	Glu Met Glu Ile Ala Leu Arg Ser Leu Phe Thr Arg Ile Pro Gln Leu				
	355	360	365		
	cgc ctc gcc gta cgc gcc gcc gag att cgc ttc aag gac gga gac acc				1571
	Arg Leu Ala Val Pro Ala Ala Glu Ile Pro Phe Lys Asp Gly Asp Thr				
15	370	375	380		
	cta caa gcc atg atc gaa cta cgc cta gcc tgg tag cagccaggac ggcaga				1623
	Leu Gln Gly Met Ile Glu Leu Pro Leu Ala Trp				
	385	390	395		
	ccaaagaag ggttcgga atg cgc atc gcc atc gac acc gac cgc tgt atc				1675
	Met Arg Ile Ala Ile Asp Thr Asp Arg Cys Ile				
20	400	405			
	ggc gcc gcc cag tgt gcc cta acc gcc ccc ggc ggt ttc acc cag gat				1723
	Gly Ala Gly Gln Cys Ala Leu Thr Ala Pro Gly Gly Phe Thr Gln Asp				
	410	415	420		
	gac gac ggt ttc agt gca cta cta ccc gcc cgc gag gac gcc gcc gcc				1771
	Asp Asp Gly Phe Ser Ala Leu Leu Pro Gly Arg Glu Asp Gly Ala Gly				
25	425	430	435		
	gac cgc cta gta cgc gaa gcc gcc gcc gcc tgc ccc gta cgc gcc att				1819
	Asp Pro Leu Val Arg Glu Ala Ala Arg Ala Cys Pro Val Gln Ala Ile				
	440	445	450		
	gca gtc acc gac gat tag cagcaccgcc ggcgacgcc cgcagacgc gcgcggcc				1875
	Ala Val Thr Asp Asp				
30	455				
	ccgctgaca ccggcgccc gagcgcgcc cagcgctgc gccctctcac ttgtccctac				1935
	ggcatccacc ccatccgcta ccgcaacacc ccttggtga cggcgagitt cggcgacccc				1985
	gggtgcccgg ggcctactga gtgacctga ccgcttacc ggcgcatgg ccacatagg				2055
	ctctctgctt cgcgcgcatc acgaaacgcg gtccgttccc cgcctctgaa cggctccaca				2115
	tgcccgagcg ttccacgctg aaccctcgcc ccacatcgcc caccgccgcc gggccacaca				2175
	acaggtgcac cagctcttct ctccgttctg gcgcgacalc gttagcgttg gcgaacagca				2235
35	ccagcttgct ccccgcatcc gcggacccct gcgccgcccc ggccttcggc gaggcaacct				2295
	tcagcttcac ctctggcgcc cccaccactg cgac				2329

<210> 3  
 <211> 1860  
 <212> DNA  
 <213> Unknown

<220>  
 <221> CDS  
 <222> (172).. (1383)  
 <223> A-1560 strain

<220>  
 <221> CDS  
 <222> (1399).. (1593)

<400> 3

cgaggatcgt acgcatcacc gtttcgggc aaccgaatla cgaicggaa tggatggtt 60  
 ccagccagat ccgcagga ggcgactcgg ccgaacttga ttctatgcac tagatgcctt 120  
 ggcaatctaa tgaagatcgg cagcagccat ccttcgtctg cagagctccc c atg aca 177  
 Met Thr  
 1

5	gac acg aga gac ctg acc gag ctg tca gat ccc gtc tcc ttc ccc cag Asp Thr Thr Asp Leu Thr Glu Leu Ser Asp Pro Val Ser Phe Pro Gln	225
	5 10 15	
	gac cgg agc tgc ccc tac cac cgg ccc acc ggg tac gac cgg ctg cgc Asp Arg Ser Cys Pro Tyr His Pro Pro Thr Gly Tyr Asp Pro Leu Arg	273
	20 25 30	
10	acc gaa cgg cgg ccc gcc cgc atc cgg ctg tac gac ggc cgc ccc gcc Thr Glu Arg Pro Pro Ala Arg Ile Arg Leu Tyr Asp Gly Arg Pro Ala	321
	35 40 45 50	
	tgg ctg gtc acc ggc cac gcc gtc gcc cgt gac ctg ctg gtc gac cgc Trp Leu Val Thr Gly His Ala Val Ala Arg Asp Leu Leu Val Asp Pro	369
	55 60 65	
15	cgc ctg tcc acg gac cgc acc cgc tgg ggc ttc cgg gcc aca act ccc Arg Leu Ser Thr Asp Arg Thr Arg Ser Gly Phe Pro Ala Thr Thr Pro	417
	70 75 80	
	cgc ttc gcc cgc gtc cgc gac cgc aag cgg cgc ctg ctg ggc gtc gac Arg Phe Ala Ala Val Arg Asp Arg Lys Pro Ala Leu Leu Gly Val Asp	465
	85 90 95	
20	gac ccc agc cac cgc acc cag cgg tgg atg atg atc cgc agc ttc acc Asp Pro Lys His Arg Thr Gln Arg Trp Met Met Ile Pro Ser Phe Thr	513
	100 105 110	
	ctc agc cgc gcc acc gag ctg agc cgc cgc atc cag gag atc gtc gac Leu Arg Arg Ala Thr Glu Leu Arg Pro Arg Ile Gln Glu Ile Val Asp	561
	115 120 125 130	
25	gaa ctg ctg gac gtc atg atc gcc cag gga ccc cgg gcc gac ctg gtc Glu Leu Leu Asp Val Met Ile Ala Gln Gly Pro Pro Ala Asp Leu Val	609
	135 140 145	
	cbl tcc ttc cgc ctg cgg gtc cgg tcc atg gtc atc tgc gcc ctg ctg Gly Ser Phe Ala Leu Pro Val Pro Ser Met Val Ile Cys Ala Leu Leu	657
	150 155 160	
30	ggc gtc ccc tac gcc gac cac gag ttc ttc gag gac cag tcc agc cgg Gly Val Pro Tyr Ala Asp His Glu Phe Phe Glu Asp Gln Ser Arg Arg	705
	165 170 175	
	ctg ctg cgc gga cgg cgc gcc gag gac acg cag gac gcc cgg gac cgg Leu Leu Arg Gly Pro Ala Ala Glu Asp Thr Gln Asp Ala Arg Asp Arg	753
	180 185 190	
35	ctc gcc ggc tac ctg gag gac ctg atc gac ggg aag cgg cgc cgg ccc Leu Ala Ala Tyr Leu Glu Asp Leu Ile Asp Glu Lys Arg Arg Arg Pro	801
	195 200 205 210	
	ggt gac ggc ctg ctg gac gaa ctg gtc cag cag cgt ctg aac gaa ggc Gly Asp Gly Leu Leu Asp Glu Leu Val Gln Gln Arg Leu Asn Glu Gly	849
	215 220 225	
40	gag ctg gac cgg gag gaa ctg acc ggc ctg cgc atg atc ctg ctg gtc Glu Leu Asp Arg Glu Glu Leu Thr Ala Leu Ala Met Ile Leu Leu Val	897
	230 235 240	
	gcg ggc cac gag acc acc gcc aac atg atc tcc ctg ggc acc tac acg Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser Leu Gly Thr Tyr Thr	945
	245 250 255	
45	ctc ctg ctg cac ccc gaa cgg ctg acc gag ctg cgc gcc gac ccc cgc Leu Leu Leu His Pro Glu Arg Leu Thr Glu Leu Arg Ala Asp Pro Ala	993
	260 265 270	
	ctg ctg cgg gcc gcc gtc gag gaa ctg atg cgg alg ctg tcc atc gcc Leu Leu Pro Ala Ala Val Glu Glu Leu Met Arg Met Leu Ser Ile Ala	1041
	275 280 285 290	
50	gac gga ctg ctg cgg cag gcc acc gag gac atc gag atc gcc ggg acc Asp Gly Leu Leu Arg Gln Ala Thr Glu Asp Ile Glu Ile Ala Gly Thr	1089
	295 300 305	
	acc atc agc gcc ggc gac gcc gtc gtc tcc acc tct gtc atc aac Thr Ile Arg Ala Gly Asp Gly Val Val Phe Ser Thr Ser Val Ile Asn	1137
	310 315 320	
55	cgc gac gag gac gtc tac cgg gcc ccc gac acc ctg gac ttc cac cgc	1185

Arg Asp Glu Asp Val Tyr Pro Ala Pro Asp Thr Leu Asp Phe His Arg  
 325 330 335  
 5 tgc acc cgc cac cac gtc gcc ttc ggt ttc gga atc cac cag tgc ctc 1233  
 Ser Thr Arg His His Val Ala Phe Gly Phe Gly Ile His Gln Cys Leu  
 340 345 350  
 ggc cag aac ctc gcc cgc acc gaa ctg gag atc gcc ctg cgc acg ctc 1281  
 Gly Gln Asn Leu Ala Arg Thr Glu Leu Glu Ile Ala Leu Arg Thr Leu  
 355 360 365 370  
 10 ctc gaa cgg ctg ccc acg ctc cgg ctc gcc gcc cca cgg gag gaa atc 1329  
 Glu Glu Arg Leu Pro Thr Leu Arg Leu Ala Pro Pro Glu Glu Ile  
 375 380 385  
 ccc ttc aaa ccc gcc gac acc atc cag ggg atg ctg gaa ctc ccc gtc 1377  
 Pro Phe Lys Pro Gly Asp Thr Ile Gln Gly Met Leu Glu Leu Pro Val  
 390 395 400  
 15 agc tgg taa gagctgccg tc atg cat atc gag atc gac aag gac cgc tgc 1428  
 Ser Trp Met His Ile Glu Ile Asp Lys Asp Arg Cys  
 405 410  
 atc gcc gcc gga cag tgc gcc ctg acc gcc cgg ggt gtg ttc acc cag 1476  
 Ile Gly Ala Gly Gln Cys Ala Leu Thr Ala Pro Gly Val Phe Thr Gln  
 420 425 430  
 gac gac gac gcc ttc agt gac ctg ttc ccc gcc cgg gag gac gcc gcc 1524  
 Asp Asp Asp Gly Phe Ser Asp Leu Leu Pro Gly Arg Glu Asp Gly Ala  
 435 440 445  
 ggc gac cgg atg gtc cgg gag gcc gcc ggg gcc tgc ccc gtg agt gcc 1572  
 Gly Asp Pro Met Val Arg Glu Ala Ala Arg Ala Cys Pro Val Ser Ala  
 450 455 460  
 25 atc acg ctg tcc gag gac ggg tag gggcccgagc cgcgccgcc gccgctccgc 1626  
 Ile Thr Leu Ser Glu Asp Gly  
 465  
 tccgcgcgc cctctccgac gggccggccc gccgccctt cggctccgc tccctccgc 1686  
 cctgcccgc ggcgcgact gattgactg gcttcccgg tggcgagaa gggccagag 1746  
 ccttccggg cggcccgcc gaaagacac gggacggcg cggggaacc ccttcctta 1806  
 cgctccttc tgcgcgcc gcatcgccg aggcgtcagc aagctgata cgc 1860

<210> 4  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> STRANDNESS : single  
  
 <220>  
 <223> TOPOLOGY : linear  
  
 <220>  
 <223> Description of Artificial Sequence : 50m-3F Primer  
  
 <400> 4  
 ttgcscctc-csgtccctc satggtat

29

<210> 5  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> STRANDNESS : single

<220>  
 <223> TOPOLOGY : linear  
 5  
 <220>  
 <223> Description of Artificial Sequence : 5Dm-3R Primer  
 <400> 5  
 10 gllgalsays gasgtsgaga a 21  
 <210> 6  
 <211> 30  
 <212> DNA  
 15 <213> Artificial Sequence  
 <220>  
 <223> STRANDNESS : single  
 <220>  
 20 <223> TOPOLOGY : linear  
 <220>  
 <223> Description of Artificial Sequence : 6PIN-2F Primer  
 <400> 6  
 25 gcctgcacctg gccctggagg acatcgagat 30  
 <210> 7  
 <211> 30  
 <212> DNA  
 30 <213> Artificial Sequence  
 <220>  
 <223> STRANDNESS : single  
 <220>  
 35 <223> TOPOLOGY : linear  
 <220>  
 <223> Description of Artificial Sequence : 6PIN-2R Primer  
 <400> 7  
 40 ctgttcctcg aagaactcgt gctgcgcgtg 30  
 <210> 8  
 <211> 30  
 45 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> STRANDNESS : single  
 50 <220>  
 <223> TOPOLOGY : linear  
 <220>  
 55 <223> Description of Artificial Sequence : DN-NdeF Primer  
 <400> 8

```

      gcccccatat gacggaactg acggacatca                                30
5
  <210>      9
  <211>      30
  <212>      DNA
  <213>      Artificial Sequence
10
  <220>
  <223>      STRANONESS : single
  <220>
  <223>      TOPOLOGY : linear
15
  <220>
  <223>      Description of Artificial Sequence : DM-SpeR Primer
  <400>      9
  ggccactag tcaagccgccc ggttcggtca                                30
20
  <210>      10
  <211>      30
  <212>      DNA
  <213>      Artificial Sequence
25
  <220>
  <223>      STRANDNESS : single
  <220>
  <223>      TOPOLOGY : linear
30
  <220>
  <223>      Description of Artificial Sequence : DM-BglI Primer
  <400>      10
  cccatagatc ttcaccccgag cgggtgatca                                30
35
  <210>      11
  <211>      30
  <212>      DNA
  <213>      Artificial Sequence
40
  <220>
  <223>      STRANDNESS : single
  <220>
  <223>      TOPOLOGY : linear
45
  <220>
  <223>      Description of Artificial Sequence : DM-BglI Primer
  <400>      11
  tcccagatc ttgaaggtcc cgttcacgt                                30
50
  <210>      12
  <211>      22
  <212>      DNA
  <213>      Artificial Sequence
55

```

```

5      <220>
      <223> STRANDNESS : single

      <220>
      <223> TOPOLOGY : linear

10     <220>
      <223> Description of Artificial Sequence : 5D-1R Primer

      <400> 12
      aggtgccctag cgagatcatg tt                22

15     <210> 13
      <211> 30
      <212> DNA
      <213> Artificial Sequence

20     <220>
      <223> STRANDNESS : single

      <220>
      <223> TOPOLOGY : linear

25     <220>
      <223> Description of Artificial Sequence : 7PIN-2F Primer

      <400> 13
      ccatgatcct gctggtgccc ggccatgaga        30

30     <210> 14
      <211> 30
      <212> DNA
      <213> Artificial Sequence

35     <220>
      <223> STRANDNESS : single

      <220>
      <223> TOPOLOGY : linear

40     <220>
      <223> Description of Artificial Sequence : 07-Ndef Primer

      <400> 14
      gcccctatg accgaagcca tccctactt          30

45     <210> 15
      <211> 30
      <212> DNA
      <213> Artificial Sequence

      <220>
      <223> STRANDNESS : single

55     <220>
      <223> TOPOLOGY : linear

```

<220>  
 <223> Description of Artificial Sequence : 07-SpeR Primer  
 5 <400> 15  
 gccactagtg ctaatcgctg gtgaccgcaa 30  
  
 <210> 16  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> STRANDNESS : single  
 15  
  
 <220>  
 <223> TOPOLOGY : linear  
  
 <220>  
 <223> Description of Artificial Sequence : 50m-2R Primer  
 20  
 <400> 16  
 ctggatgtg tcscsbgyl t 21  
  
 <210> 17  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> STRANDNESS : single  
 30  
  
 <220>  
 <223> TOPOLOGY : linear  
  
 <220>  
 <223> Description of Artificial Sequence : 5PIN-2F Primer  
 35  
 <400> 17  
 cggaaaccac cagtgcctcg gccagaacct 30  
  
 <210> 18  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> STRANDNESS : single  
 45  
  
 <220>  
 <223> TOPOLOGY : linear  
  
 <220>  
 <223> Description of Artificial Sequence : tpm-NdeF Primer  
 50  
 <400> 18  
 agccccatai gacagacag acagacctga 30  
 55




<210> 19  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> STRANDNESS : single  
  
 <220>  
 <223> TOPOLOGY : linear  
  
 <220>  
 <223> Description of Artificial Sequence : tm-SpeR Primer  
  
 <400> 19  
 gcgcgactag tccccctacc cgtccicgga


30

# Claims

1. A DNA participating in biological transformation of a macrolide compound (hereinafter referred to as a macrolide compound 11107B) represented by the formula (I):



into a 16-position hydroxy macrolide compound represented by the formula (II):



the DNA being an isolated and pure DNA comprising a DNA encoding a protein having 16-position hydroxylating

enzymatic activity or ferredoxin, partly or entirely or its variant.

2. The DNA according to Claim 1, which is **characterized by** the following (a), (b) or (c):

(a) a DNA encoding a protein having the enzymatic activity in hydroxylating the 16-position of the macrolide compound 11107B and selected from the group consisting of a continuous nucleotide sequence from the base 1322 to base 2548 of the sequence No. 1; a continuous nucleotide sequence from the base 420 to base 1604 of the sequence No. 2; and a continuous nucleotide sequence from the base 172 to base 1383 of the sequence No. 3;

(b) a DNA which is a variant of the DNA described in the above (a);

(i) is hybridized with the DNA described in the above (a) under a stringent condition; and  
(ii) encodes a protein having enzymatic activity in hydroxylating the 16-position of the macrolide compound 11107B; and

(c) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA described in the above (a) or (b) though it is not hybridized with the DNA described in the above (a) under a stringent condition because of the degeneracy of a gene codon.

3. A protein encoded by the DNA as claimed in Claim 2.

4. A self-replicative or integrating replicative recombinant plasmid carrying the DNA as claimed in Claim 2.

5. A transformant into which the recombinant plasmid as claimed in Claim 4 transforms.

6. A method of isolating a DNA encoding a protein having enzymatic activity in hydroxylating the 16-position of the macrolide compound 11107B, the method **characterized by** using the DNA as claimed in Claim 2 or a DNA constituted of a part of the DNA as a probe or a primer.

7. The DNA according to Claim 1, which is **characterized by** the following (d), (e) or (f):

(d) a DNA encoding ferredoxin and selected from the group consisting of a continuous nucleotide sequence from the base 2564 to base 2761 of the sequence No. 1, a continuous nucleotide sequence from the base 1643 to base 1834 of the sequence No. 2 and a continuous nucleotide sequence from the base 1399 to base 1593 of the sequence No. 3;

(e) a DNA which is a variant of the DNA represented by the above (d);

(i) is hybridized with the DNA described in the above (d) under a stringent condition; and  
(ii) encodes a protein having a ferredoxin function; and

(f) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA represented by the above (d) or (e) though it is not hybridized with the DNA described in the above (d) under a stringent condition because of the degeneracy of a gene codon.


8. A protein encoded by the DNA as claimed in Claim 7.

9. A self-replicative or integrating replicative recombinant plasmid carrying the DNA as claimed in Claim 7.


10. A transformant into which the recombinant plasmid as claimed in Claim 9 transforms.

11. A method of isolating a DNA encoding a protein having a ferredoxin function, the method **characterized by** using the DNA as claimed in Claim 7 or a DNA constituted of a part of the DNA as a probe or a primer.

12. A method of producing a 16-position hydroxy macrolide compound, the method comprises the steps of culturing the transformant as claimed in Claim 5 or 10 in a medium; bringing the proliferated transformant into contact with a macrolide compound represented by the formula (III):



10 (wherein W represents



20  $R^{12}$ ,  $R^{16b}$ ,  $R^{17a}$ ,  $R^{17b}$ ,  $R^{18}$ ,  $R^{20a}$ ,  $R^{20b}$ ,  $R^{21a}$  and  $R^{21b}$ , which may be the same as or different from, respectively represent:

- (1) hydrogen atom;  
 (2) a  $C_{1-22}$  alkyl group which may have a substituent;  
 (3) -OR (wherein R represents:

- 1) hydrogen atom; or  
 2) a  $C_{1-22}$  alkyl group;  
 3) a  $C_{7-22}$  aralkyl group;  
 4) a 5-membered to 14-membered heteroaryloxyalkyl group;  
 5) a  $C_{2-22}$  alkanoyl group;  
 6) a  $C_{7-15}$  aryl group;  
 7) a  $C_{2-22}$  unsaturated alkanoyl group;  
 8) -COR<sup>29</sup> (wherein R<sup>29</sup> represents:

- 8-1) a 5-membered to 14-membered heteroaryloxyaryl group;  
 8-2) a  $C_{1-22}$  alkoxy group;  
 8-3) an unsaturated  $C_{2-22}$  alkoxy group;  
 8-4) a  $C_{6-14}$  aryloxy group;  
 8-5) a 5-membered to 14-membered heteroaryloxy group; or  
 8-6) a 3-membered to 14-membered nitrogen-containing non-aromatic heterocyclic group, each of which may have a substituent);

- 9) a  $C_{1-22}$  alkylsulfonyl group;  
 10) a  $C_{6-14}$  arylsulfonyl group; or  
 11) -Si(R<sup>31</sup>)R<sup>32</sup>R<sup>33</sup>, (wherein R<sup>31</sup>, R<sup>32</sup> and R<sup>33</sup>, which may be the same as or different from, respectively represent a  $C_{1-6}$  alkyl group or a  $C_{6-14}$  aryl group), each of which may have a substituent);

- (4) a halogen atom; or  
 (5) -R<sup>M</sup>-NR<sup>N1</sup>R<sup>N2</sup>, (wherein R<sup>M</sup> represents a single bond or -O-CO-; and R<sup>N1</sup> and R<sup>N2</sup>

1) may be the same as or different from, respectively represent:

- 1-1) hydrogen atom; or  
 1-2)

- (i) a  $C_{1-22}$  alkyl group;  
 (ii) an unsaturated  $C_{2-22}$  alkyl group;

- (iii) a C<sub>2-22</sub> alkanoyl group;
- (iv) a C<sub>7-15</sub> aroyl group;
- (v) an unsaturated C<sub>3-22</sub> alkanoyl group;
- (vi) a C<sub>6-14</sub> aryl group;
- (vii) a 5-membered to 14-membered heteroaryl group;
- (viii) a C<sub>7-22</sub> alkyl group;
- (ix) a C<sub>1-22</sub> alkylsulfonyl group; or
- (x) a C<sub>6-14</sub> arylsulfonyl group, each of which may have a substituent, or

2) and R<sup>N1</sup> and R<sup>N2</sup> may be combined with the nitrogen atom to which they bound, to form a 3-membered to 14-membered nitrogen-containing non-aromatic heterocyclic group), provided that R<sup>21a</sup> and R<sup>21b</sup> may be combined with each other to form (i) a ketone structure (=O) or (ii) an oxime structure (=NOR<sup>x</sup>) (wherein R<sup>x</sup> represents a C<sub>1-22</sub> alkyl group, an unsaturated C<sub>2-22</sub> alkyl group, a C<sub>6-14</sub> aryl group, a 5-membered to 14-membered heteroaryl group or a C<sub>7-22</sub> alkyl group, each of which may have a substituent); R<sup>16a</sup> represents hydrogen atom; R<sup>21c</sup> represents:


- (1) hydrogen atom; or
- (2)



(wherein R<sup>22a</sup>, R<sup>22b</sup> and R<sup>22c</sup>, which may be the same as or different from, respectively represent:


- 1) hydrogen atom;
- 2) a C<sub>1-6</sub> alkyl group;
- 3) -OR (wherein R has the same meaning as the above);
- 4) -R<sup>M</sup>-NR<sup>N1</sup>R<sup>N2</sup> (wherein R<sup>M</sup>, R<sup>N1</sup> and R<sup>N2</sup> have the same meanings as the above); or
- 5) a halogen atom, or

any one of R<sup>21a</sup> and R<sup>21b</sup> may be combined with any one of R<sup>22a</sup> and R<sup>22b</sup> to form the partial structure;



); and G<sup>m</sup> represents:

- (1) a group represented by the formula (GM-I):



(wherein

$R^2$  and  $R^{10}$ , which may be the same as or different from, respectively represent hydrogen atom or a  $C_{1-22}$  alkyl group;

$R^{5a}$ ,  $R^{3a}$ ,  $R^{5b}$ ,  $R^{5b}$ ,  $R^{6a}$  and  $R^{6b}$ , which may be the same as or different from, respectively represent:

- 1) hydrogen atom;
- 2) hydroxyl group;
- 3)

3-1) a  $C_{1-22}$  alkyl group;

3-2) a  $C_{1-22}$  alkoxy group;

3-3) a  $C_{6-14}$  aryloxy group;

3-4) a 5-membered to 14-membered heteroaryloxy group;

3-5) a  $C_{2-22}$  alkanoyloxy group;

3-6) a  $C_{7-15}$  aroyloxy group;

3-7) a  $C_{3-23}$  unsaturated alkanoyloxy group;

3-8)  $-OCOR^{60}$  (wherein  $R^{60}$  has the same meaning as the above);

3-9) a  $C_{1-22}$  alkylsulfonyloxy group;

3-10) a  $C_{6-14}$  arylsulfonyloxy group; or

3-11)  $-OS(R^{61}R^{62}R^{63})$  (wherein  $R^{61}$ ,  $R^{62}$  and  $R^{63}$  have the same meanings as the above), each of which may have a substituent;


4) a halogen atom; or

5)  $-R^M-NR^{N1}R^{N2}$  (wherein  $R^M$ ,  $R^{N1}$  and  $R^{N2}$  have the same meanings as the above); or


$R^{5a}$  and  $R^{5b}$  may be combined with each other to form a ketone structure ( $=O$ ); or

$R^{6a}$  and  $R^{6b}$  may be combined with each other to form a spirooxysilanyl group or an exomethylene group; or  $R^{7a}$  and  $R^{7b}$ , which may be the same as or different from, respectively represent hydrogen atom or  $-OR^H$  (wherein  $R^H$  represents hydrogen atom, a  $C_{1-22}$  alkyl group or a  $C_{2-22}$  alkanoyl group)];


(2) a group represented by the formula (GM-II) :




(wherein  $R^2$ ,  $R^{3a}$ ,  $R^{5a}$ ,  $R^{6a}$ ,  $R^{7a}$ ,  $R^{7b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I));  
(3) a group represented by the formula (GM-III):




(wherein  $R^2$ ,  $R^{5a}$ ,  $R^{6a}$ ,  $R^{7a}$ ,  $R^{7b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I));  
(4) a group represented by the formula (GM-IV):



(wherein  $R^2$ ,  $R^{6a}$ ,  $R^{7a}$ ,  $R^{7b}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I)); or  
(5) a group represented by the formula (GM-V):




(wherein  $R^2$ ,  $R^{3a}$ ,  $R^{5a}$ ,  $R^{6a}$  and  $R^{10}$  have the same meanings as those in the formula (GM-I)); during or after culturing, to convert it into a 16-position hydroxy macrocyclic compound represented by the formula (IV):



(wherein W, R<sup>12</sup>, R<sup>16a</sup>, R<sup>17a</sup>, R<sup>17b</sup>, R<sup>20a</sup>, R<sup>20b</sup>, R<sup>21a</sup>, R<sup>21b</sup>, R<sup>21c</sup> and G<sup>m</sup> have the same meanings as those in the formula (II)); and then collecting the 16-position hydroxy macrolide compound thus converted.

13. A production method according to Claim 12, wherein the transformant is the transformant as claimed in Claim 5 and has a DNA encoding ferredoxin.

14. The production method according to Claim 12, the method comprises the step of converting a compound represented by the formula (III-a);




(wherein



represents a double bond or a single bond; W' represents a double bond or



; R<sup>5'</sup> represents hydrogen atom or an acetoxy group; R<sup>6'</sup> represents hydrogen atom or hydroxyl group; and R<sup>7'</sup> represents hydrogen atom or acetyl group) into a compound represented by the formula (IV-a);



(wherein



5 , W<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> have the same meanings as those in the formula (III-a).

15. The production method according to Claim 14, wherein, in the conversion of the compound of the formula (III-a) into the compound of the formula (IV-a), the compound to be subjected is a compound selected from the group consisting of:

10

(1) a compound in which

15



20

is a single bond; W<sup>1</sup> is



25

and R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are respectively hydrogen atom;  
(2) a compound in which

30



35

is a single bond; W<sup>1</sup> is



40

45

R<sup>5</sup> and R<sup>6</sup> are respectively hydrogen atom; and R<sup>7</sup> is acetyl group;  
(3) a compound in which

50



55

is a single bond; W<sup>1</sup> is





$R^5$  and  $R^7$  are respectively hydrogen atom; and  $R^6$  is hydroxyl group;  
(4) a compound in which



is a single bond;  $W$  is



$R^5$  is hydrogen atom,  $R^6$  is hydroxy group; and  $R^7$  is acetyl group;  
(5) a compound in which



is a single bond;  $W$  is a double bond; and  $R^5$ ,  $R^6$  and  $R^7$  are respectively hydrogen atom;  
(6) a compound in which



is a single bond;  $W$  is a double bond;  $R^5$  and  $R^6$  are respectively hydrogen atom; and  $R^7$  is acetyl group;  
(7) a compound in which



is a single bond;  $W$  is a double bond;  $R^5$  and  $R^7$  are respectively hydrogen atom; and  $R^6$  is hydroxyl group;  
(8) a compound in which



is a single bond;  $W$  is a double bond;  $R^5$  is hydrogen atom;  $R^6$  is hydroxy group; and  $R^7$  is acetyl group;  
(9) a compound in which



5

is a double bond; W' is

10



15

; R<sup>5</sup> and R<sup>7</sup> are respectively hydrogen atom; and R<sup>6</sup> is hydroxyl group;  
(10) a compound in which

20



is a double bond; W' is

25



30

R<sup>5</sup> is hydrogen atom; R<sup>6</sup> is hydroxy group; and R<sup>7</sup> is acetyl group;  
(11) a compound in which

35



40

is a single bond; W' is

45



50

R<sup>5</sup> is acetoxy group; R<sup>6</sup> is hydroxyl group; and R<sup>7</sup> is hydrogen atom; and  
(12) a compound in which

55



is a single bond; W' is



5

$R^{5'}$  is an acetoxy group;  $R^{6'}$  is hydroxyl group; and  $R^{7'}$  is acetyl group.

10 16. Use of the transformant as claimed in Claim 5 or 10 for producing a 16-position hydroxy macrolide compound.

15

20

25

30

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/017306

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.<sup>7</sup> C12N15/09, 1/15, 1/19, 1/21, 5/10, 9/02, C12P17/08, C07K14/00, C07D407/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.<sup>7</sup> C12N1/00-15/19, C12P17/08, C07K14/00-16/46, C07D407/16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

SwissProt/PIR/GeneSeq, MEDLINE (STN), Genebank/EMBL/DDBJ/GeneSeq, WPI (STN), BICISIS (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/ A	WO 2003/040370 A1 (SUMITOMO CHEMICAL CO., LTD.), 15 May, 2003 (15.05.03), Full text & JP 2004-57194 A & EP 1457558 A1	1-11/ 12-16
P, A	WO 2003/099813 A1 (MERCIAN CO.), 04 December, 2003 (04.12.03), (Family: none)	1-16
A	WO 2002/060890 A1 (MERCIAN CO.), 08 August, 2002 (08.08.02), (Family: none)	1-16
P, A	WO 2004/050890 A1 (MERCIAN CO.), 17 June, 2004 (17.06.04), (Family: none)	1-16

☒ Further documents are listed in the continuation of Box C.☐ See patent family scanner.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent but published on or after the international filing date

"C" document which may throw doubts as to priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"D" document referring to an oral disclosure, use, exhibition or other means

"E" document published prior to the international filing date but later than the priority date claim

"F" inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"G" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"H" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"I" document member of the same patent family

Date of the actual completion of the international search  
21 February, 2005 (21.02.05)Date of mailing of the international search report  
08 March, 2005 (08.03.05)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JE2004/017906

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 2004/011459 A1 (MERCIAN CO.), 05 February, 2004 (05.02.04), (Family: none)	1-16
P, A	WO 2004/011661 A1 (MERCIAN CO.), 05 February, 2004 (05.02.04), (Family: none)	1-16
A	WO 2003/087381 A1 (MERCIAN CO.), 23 October, 2003 (23.10.03), & EP 1500704 A1	1-16

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

Patent documents cited in the description

- WO 02060890 A [0002]
- WO 03087381 A [0085] [0120] [0141]

Non-patent literature cited in the description

- Molecular Cloning, Current Protocols in Molecular Biology, John Wiley & Sons, 1987 [0032]
- *Cell Technology*, 1995, vol. 14, 591-593 [0075] [0110] [0131]